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ABSTRACT

The present disclosure provides a DNA vaccine or immu
nogenic composition expressing consensus hemagglutinin
esterase - fusion (HEF ) protein (FluD - Vax ) and a protein
based vaccine utilizing the HEF consensus protein . Methods
of making and using the compositions are also provided

herein .

20 Claims , 7 Drawing Sheets
Specification includes a Sequence Listing .
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DEVELOPMENT OF A PREVENTIVE
INFLUENZA D VIRUS VACCINE

most devastating diseases of the cattle population . An effi

STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH OR DEVELOPMENT

potential cross - species transmission . In this study, a DNA

None .

BACKGROUND

Influenza D virus (IDV) has recently been classified as a
new genus within the Orthomyxoviridae family and is
distinct from influenza A , B , and C viruses ( IAV, IBV, ICV ,

respectively ). IDV infects economically important domestic
livestock , including swine and cattle , and has been associ
ated with a respiratory disease / influenza - like illness . Furthermore , IDV seroprevalence in humans was estimated to

IDV infection has been associated with BRDC , one of the

cacious vaccine is needed to prevent infection and stop

5 vaccine encoding the consensus HEF of two lineages of IDV
(D/ OK and D/ 660 ) ( SEQ ID NO . 1 ) was designed and its
efficacy was tested in a guinea pig model. The results
showed that the consensus DNA vaccine ( SEQ ID NO . 2 )
elicited
high - titer neutralizing antibodies and achieved ster
10
ilizing protection against two lineage - representative IDV
intra -nasal infections. It is believed that this is the first study
showing a DNA vaccine - expressing consensus HEF is effi
cacious in preventing different lineages of influenza D virus
.
15 infections
In one aspect of the disclosure, a DNA vaccine or immu
nogenic composition is provided. Preferably, the vaccine or

be approximately 1.3 % in the general population and over
90 % in individuals working with cattle. These initial studies immunogenic composition has a nucleotide sequence having
suggest that IDV may have the potential to infect humans, at least 85 % , more preferably 90% , still more preferably 91 ,
although its pathogenicity to humans remains unknown . 20 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 99.5 , or 100 % sequence
IDV has a broad host range. IDV was initially isolated homology with SEQ ID NO.2 and/or encodes an amino acid

from clinically ill pigs expressing influenza - like symptoms
in 2011. However, subsequently epidemiological data sug

gest cattle are the primary reservoir . In addition to swine and
cattle, IDV infections have been reported in goat , sheep,
equine, buffalo , and camel . IDV has also been shown to

infect ferrets and guinea pigs in experimental settings . IDV
infections are widely distributed across many countries in
the American , Asian , European , and African continents .
With a broad host range and high environmental stability,
IDV has the potential to further gain virulence, or even infect
humans.
Two lineages of IDVs were found to be co - circulating in
the United States . Recently, a potential third lineage of IDV

sequence having at least 85 % , more preferably 90% , still

25

nore preferably 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 99.5 , or
100 % sequence homology with SEQ ID NO . 1 .
In another aspect of the disclosure , a protein- based vac
cine or immunogenic composition is provided . Preferably,

the vaccine or immunogenic composition is encoded by a

nucleotide sequence having at least 85 % , more preferably
90% , still more preferably 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 ,
99.5 , or 100 % sequence homology with SEQ ID NO . 2
and / or has an amino acid sequence having at least 85 % ,
more preferably 90 % , still more preferably 91 , 92 , 93 , 94 ,
95 , 96 , 97 , 98 , 99 , 99.5 , or 100 % sequence homology with
was identified in Japan . IDV, like other Influenza viruses, is
aRNA
singlevirus-strand
, negative-sense segmented and enveloped 35 SEQ another
ID NO. aspect
1. of the disclosure, a method of reducing
. Both IAV and IBV have eight genomic segments theInincidence
of or severity of clinical signs of IDV infection
and two surface glycoproteins of hemagglutinin (HA) and
neuraminidase (NA ). IDV like ICV has only seven genomic in an individual animal is provided . In general, the method
segments and one spike hemagglutinin - esterase - fusion comprises the step of administering an immunogenic com
(HEF) protein. The HEF combines the functions of HA and 40 position or vaccine to an animal in need thereof wherein the
NA for receptor binding , receptor destruction, and mem- immunogenic composition has a nucleotide sequence having
brane fusion activity. While the overall structure of IDV at least 85 % , more preferably 90% , still more preferably 91 ,
HEF is similar to ICV, IDV HEF has an open receptor 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 99.5 , or 100 % sequence
binding cavity to accommodate diverse extended glycan homology with SEQ ID NO . 2 and / or encodes an amino acid
moieties
range . , which may be one of the reasons for its broad host 45 sequence having at least 85 % , more preferably 90 % , still
preferably 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 99.5 , or
IDV causes only mild or no obvious clinical symptoms in more
100
%
sequence homology with SEQ ID NO . 1. In some
infected animals. However, it is thought to be a facilitating forms, the
sequence is combined with a carrier. In
factor for the development of bovine respiratory disease some formsnucleotide
, the nucleotide sequence is combined with an
complex ( BRDC ) , which is one of the most commonly
30

diagnosed causes of morbidity and mortality within the 50 adjuvant
. In some forms, the nucleotide sequence is con
tained within a vector . In some forms, the vector is a

cattle industry. An efficacious preventative vaccine is needed

to protect economically important domestic animals and plasmid . In some forms, the vector is the pJW4303 vector.
In another aspect of the disclosure, a method of reducing
limit potential cross - species transmission to humans.
What is needed is an immunogenic composition that the incidence of or severity of clinical signs of IDV infection
provides
protection against IDV infection and/or reduces at 55 in a group or herd of animals is provided . In general, the
least one of the following: the incidence of IDV infection , method comprises the step of administering an immuno
the severity of clinical signs caused by or associated with genic composition or vaccine to a group of animals in need
IDV infection , the incidence of clinical signs caused by or thereof wherein the immunogenic composition has a nucleo
associated with IDV infection , and the susceptibility to IDV tide sequence having at least 85 % , more preferably 90 % ,
infection . What is further needed is an immunogenic com- 60 still more preferably 91 , 92, 93 , 94, 95 , 96 , 97 ,98, 99 , 99.5 ,
position that reduces the possibility of cross - species trans- or 100% sequence homology with SEQ ID NO . 2 and / or
encodes an amino acid sequence having at least 85 % , more
mission of IDV to other animals including humans.
preferably 90 % , still more preferably 91 , 92 , 93 , 94 , 95 , 96 ,
SUMMARY OF THE DISCLOSURE
97 , 98 , 99 , 99.5 , or 100 % sequence homology with SEQ ID
65 NO . 1. In some forms, the nucleotide sequence is combined
The present disclosure overcomes the problems inherent with a carrier. In some forms, the nucleotide sequence is
in the art including those described above.
combined with an adjuvant. In some forms, the nucleotide

US 10,960,069 B2
3

4

sequence is contained within a vector. In some forms, the

with SEQ ID NO . 1. In some forms, the amino acid sequence

position or vaccine to an animal in need thereof wherein the

In another aspect of the disclosure, the immunogenic

some forms, the amino acid sequence is combined with a
carrier. In some forms, the amino acid sequence is combined
with an adjuvant.
In another aspect of the disclosure, a method of reducing

same container or administration vehicle . In some forms, the
other antigen is administered concurrently or within 5 min
utes , 1 hour, 3 hours , 5 hours, 10 hours, 18 hours , 24 hours ,
36 hours , 48 hours , 72 hours , or 96 hours of the adminis

in a group or herd of animals is provided. In general, the
method comprises the step of administering an immunogenic composition or vaccine to a group of animals in need
thereof wherein the immunogenic composition is encoded
by a nucleotide sequence having at least 85 % , more pref- 25

present disclosure. In some forms, the pathogen is selected
from the group consisting of at least one swine pathogen ,
preferably one described below and / or at least one cattle
pathogen , preferably selected from the group consisting of
Bovine Viral Diarrhea Virus, Bovine Herpesvirus, Pasteur
ella , Mannheimia, Bluetongue Virus, Bovine Parvovirus,
Bovine Parainfluenza Virus, Bovine Respiratory Syncytial
Virus, and Fusobacterium .
In another aspect of the disclosure a method of producing
and / or recovering recombinant HEF IDV protein is pro
vided . In general, the method includes the steps of 1 )
infecting a number of susceptible cells in culture with a
recombinant viral vector encoding a HEF IDV protein , 2 )
expressing HEF IDV protein by the recombinant viral vec
tor, 3 ) recovering the HEF IDV protein , and , 4 ) separating
cell debris from the expressed HEF IDV protein via a
separation step .
In another aspect of the present disclosure , the inclusion
of an inactivation step is preferred in order to inactivate the
viral vector prior to recovery of HEF IDV protein that will
be used in an immunogenic or immunological composition
such as a vaccine . Such a step can be performed as step 5 )
in addition to steps 1-4 described above .
In some forms, this inactivation is done either just before
or just after the filtration or separation step . Any conven
tional inactivation method can be used for purposes of the
present disclosure. Thus , inactivation can be performed by
chemical and / or physical treatments . One representative
inactivation method includes the addition of cyclized binary
ethylenimine (BEI ) .
Optionally, the method described above may also include
a neutralization step after step 5 ) . For example , if the
inactivation agent is BEI , addition of sodium thiosulfate to
an equivalent amount is preferred. Preferably, the sodium
thiosulfate is added in equivalent amount as compared to the

vector is a plasmid . In some forms, the vector is the is combined with a carrier. In some forms, the amino acid
sequence is combined with an adjuvant. In some forms, the
PJW4303 vector.
In another aspect of the disclosure , a method of reducing nucleotide sequence used to express the amino acid
the incidence of or severity of clinical signs of IDV infection 5 sequence is contained within a vector. In some forms, the
in an individual animal is provided. In general, the method vector is a plasmid . In some forms, the vector is the
comprises the step of administering an immunogenic com- pJW4303 vector.

immunogenic composition is encoded by a nucleotide composition or vaccine as disclosed herein is combined with
sequence having at least 85 % , more preferably 90 % , still 10 or administered concurrently with an antigen that reduces
more preferably 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 99.5 , or the incidence of or severity of clinical signs of another
100% sequence homology with SEQ ID NO . 2 and / or has an pathogen . In some forms, the other pathogen is a virus. In
amino acid sequence having at least 85 % , more preferably some forms, the other pathogen is a bacteria . In some forms,
90 % , still more preferably 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , the immunogenic composition of the present disclosure is
99.5 , or 100 % sequence homology with SEQ ID NO . 1. In 15 combined with the other antigen such that they are in the

the incidence of or severity of clinical signs of IDV infection 20 tration of the immunogenic composition or vaccine of the

erably 90% , still more preferably 91 , 92 , 93 , 94 , 95 , 96 , 97 ,
98 , 99 , 99.5 , or 100 % sequence homology with SEQ ID NO .
2 and / or has an amino acid sequence having at least 85 % ,
more preferably 90 % , still more preferably 91 , 92 , 93 , 94 ,
95 , 96 , 97 , 98 , 99 , 99.5 , or 100 % sequence homology with 30
SEQ ID NO . 1. In some forms, the amino acid sequence is
combined with a carrier. In some forms, the amino acid
sequence is combined with an adjuvant.
In another aspect of the disclosure , a method of making an
immunogenic composition or vaccine that provides protec- 35
tion by reducing the incidence of or severity of clinical signs
of IDV infection in an individual animal or group of animals
is provided . The method generally comprises the steps of

inserting a desired nucleotide sequence into a vector and
administering the vector to an animal or animals in need
thereof. Preferably, the nucleotide sequence has at least
85 % , more preferably 90% , still more preferably 91 , 92 , 93 ,
94 , 95 , 96 , 97 , 98 , 99 , 99.5 , or 100 % sequence homology
with SEQ ID NO . 2 and / or encodes an amino acid sequence
having at least 85 % , more preferably 90 % , still more preferably 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 99.5 , or 100 %
sequence homology with SEQ ID NO . 1. In some forms, the
vector containing the nucleotide sequence is combined with
a carrier. In some forms, the vector containing the nucleotide
sequence is combined with an adjuvant. In some forms, the
vector is a plasmid . In some forms, the vector is the
pJW4303 vector. Preferably, the inserted nucleotide
sequence is expressed in vivo after being administered to the
animal or group of animals .
In another aspect of the disclosure , a method of making an
immunogenic composition or vaccine is provided . The
method generally includes the step of recovering an
expressed protein or constructing a recombinant protein and
using that protein as the immunogenic composition or
vaccine . In some forms, the protein is expressed by a
nucleotide sequence having at least 85 % , more preferably
90 % , still more preferably 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 ,
99.5 , or 100 % sequence homology with SEQ ID NO . 2. In
some forms, the expressed protein or constructed recombinant protein has an amino acid sequence having at least
85 % , more preferably 90% , still more preferably 91 , 92 , 93 ,

40
45

50

55

BEI added for inactivation .

An “ immunogenic or immunological composition ” refers

to a composition of matter that comprises at least one
antigen which elicits an immunological response in the host
60 of a cellular and / or antibody -mediated immune response to
the composition or vaccine of interest. Usually, an “ immu
nological response ” includes but is not limited to one or
more of the following effects: the production or activation of
antibodies, B cells , helper T cells , suppressor T cells , and /or
65 cytotoxic T cells and / or yd T cells , directed specifically to an
antigen or antigens included in the composition or vaccine
94 , 95 , 96 , 97 , 98 , 99 , 99.5 , or 100 % sequence homology of interest. Preferably, the host will display either a thera
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peutic or protective immunological response such that resis-

binant viral vector. In preferred forms and as described

tance to new infection will be enhanced and /or the clinical above , a neutralization step , step 8 ) , will be performed after
severity of the disease reduced . Such protection will be step 7 ) . Of course, prior to step 1 ) the HEF IDV DNA can
demonstrated by either a reduction in the severity or preva- be amplified in vitro , preferably with flanking sequences of
lence of, up to and including a lack of symptoms normally 5 the HEF IDV DNA , as described above .
displayed by an infected host , a quicker recovery time and / or
In another aspect of the present disclosure , a method for
a lowered viral titer in the infected host.
preparing a composition , preferably an immunogenic com
In preferred forms and especially in forms that will use the position , such as a vaccine , for invoking an immune
recombinant HEF IDV protein in an immunogenic compo- response against HEF IDV is provided . Generally, this
sition such as a vaccine, each lot or just selected lots of 10 method includes the steps of transfecting a construct into a
harvested HEF IDV protein can be tested for inactivation . virus, wherein the construct comprises 1 ) recombinant DNA
Thus a further aspect of the present disclosure relates to an from HEF IDV, 2 ) infecting cells in growth media with the
inactivation test for determining the effectiveness of the transfected virus, 3 ) causing the virus to express the recom
inactivation of the recombination viral vector, comprising binant protein from HEF IDV, 4 ) recovering the expressed

the steps: 1) contacting at least a portion of the culture fluid 15 recombinant protein , 5 ) and preparing the composition by

containing the recombinant viral vector with an inactivating combining the recovered protein with a suitable adjuvant
agent, 2 ) adding a neutralization agent to neutralize the and / or other pharmaceutically acceptable carrier. In some
inactivation agent, and 3 ) determining the residual infectiv- preferred forms, the composition also includes at least a
ity.
portion of the viral vector expressing said HEF IDV protein ,
In preferred forms the recombinant viral vector containing 20 and /or a portion of the cell culture supernate
HEF IDV DNA and expressing HEF IDV protein used to
“ Adjuvants ” as used herein , can include aluminum
infect the cells is generated by transfecting a transfer vector hydroxide and aluminum phosphate, saponins e.g. , Quil A ,
that has had a HEF IDV gene cloned therein into a viral QS - 21 ( Cambridge Biotech Inc. , Cambridge, Mass . ) , GPI
vector. Preferably, only the portion of the transfer vector that 0100 (Galenica Pharmaceuticals, Inc. , Birmingham , Ala . ) ,

contains the desired HEF IDV DNA is transfected into the 25 water - in - oil emulsion , oil - in -water emulsion , water-in - oil
in - water emulsion . The emulsion can be based in particular
The term “ transfected into a viral vector ” means , and is on light liquid paraffin oil ( European Pharmacopea type);

viral vector.

used as a synonym for “ introducing ” or “ cloning ” a heter-

isoprenoid oil such as squalane or squalene oil resulting

ologous DNA into a viral vector, such as for example into a from theoligomerization of alkenes, in particular of
baculovirus vector. A “ transfer vector ” means a DNA mol- 30 isobutene or decene ; esters of acids or of alcohols containing
ecule , that includes at least one origin of replication, the a linear alkyl group , more particularly plant oils , ethyl
heterologous gene, in the present case of HEF IDV, DNA oleate , propylene glycol di- (caprylate / caprate ), glyceryl tri
sequences which allow the cloning of said heterologous ( caprylate /caprate ) or propylene glycol di ate ; esters of
gene into the viral vector will be included . Preferably the branched fatty acids or alcohols , in particular isostearic acid

sequences which allow cloning of the heterologous gene into 35 esters. The oil is used in combination with emulsifiers to

the viral vector are flanking the heterologous gene . Even
more preferably, those flanking sequences are at least
homologous in parts with sequences of the viral vector. The
sequence homology then allows recombination of both
molecules , the viral vector, and the transfer vector to gen- 40
erate a recombinant viral vector containing the heterologous
gene.
In another aspect of the disclosure , a method of making
the HEF IDV protein will begin with the isolation of HEF
IDV DNA . Any HEF IDV gene can be used for purposes of 45
the present disclosure . The HEF IDV DNA is preferably
amplified using PCR methods. The resulting DNA is then
cloned into the transfer vector.

Thus, in one aspect of the present disclosure, a method for
constructing a recombinant viral vector containing HEF IDV 50
DNA is provided . This method generally comprises the steps
of: 1 ) cloning at least one recombinant HEF IDV gene into

a transfer vector ;

and 2 ) transfecting the portion of the transfer vector

containing the recombinant HEF IDV gene into a viral 55

vector, to generate the recombinant viral vector.

A further aspect of the present disclosure relates to a
method for preparing a composition comprising HEF IDV
protein , and inactivated viral vector. This method generally
comprises the steps of: 1 ) cloning the amplified HEF IDV 60
DNA into a transfer vector ; 2 ) transfecting the portion of the
transfer vector containing the recombinant HEF IDV DNA
into a virus; 3 ) infecting cells in media with the transfected
viral vector ; 4 ) causing the transfected viral vector to
expressthe recombinant protein from the HEF IDV DNA ; 5 ) 65
separating cells from the supernate ; 6 ) recovering the
expressed HEF IDV protein ; and 7 ) inactivating the recom-

form the emulsion . The emulsifiers are preferably nonionic
surfactants , in particular esters of sorbitan , of mannide (e.g.
anhydromannitol oleate ) , of glycol , of polyglycerol, of pro
pylene glycol and of oleic , isostearic, ricinoleic or hydrox
ystearic acid , which are optionally ethoxylated , and poly
oxypropylene- polyoxyethylene copolymer blocks, in
particular the Pluronic products, especially L121 . See
Hunter et al . , The Theory and Practical Application of
Adjuvants ( Ed . Stewart - Tull, D. E. S. ) . John Wiley and
Sons , NY, pp 51-94 ( 1995 ) and Todd et al . , Vaccine 15 :564

570 ( 1997 ) .
For example , it is possible to use the SPT emulsion
described on page 147 of “ Vaccine Design , The Subunit and
Adjuvant Approach ” edited by M. Powell and M. Newman ,
Plenum Press , 1995 , and the emulsion MF59 described on
page 183 of this same book.
A further instance of an adjuvant is a compound chosen
from the polymers of acrylic or methacrylic acid and the
copolymers of maleic anhydride and alkenyl derivative .
Advantageous adjuvant compounds are the polymers of
acrylic or methacrylic acid which are cross -linked, espe
cially with polyalkenyl ethers of sugars or polyalcohols .
These compounds are known by the term carbomer
(Phameuropa Vol. 8 , No. 2 , June 1996 ) . Persons skilled in
the art can also refer to U.S. Pat . No. 2,909,462 which
describes such acrylic polymers cross - linked with a poly
hydroxylated compound having at least 3 hydroxyl groups,
preferably not more than 8 , the hydrogen atoms of at least
three hydroxyls being replaced by unsaturated aliphatic
radicals having at least 2 carbon atoms . The preferred
radicals are those containing from 2 to 4 carbon atoms, e.g.
vinyls, allyls and other ethylenically unsaturated groups .

US 10,960,069 B2
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The unsaturated radicals may themselves contain other
substituents, such as methyl. The products sold under the
name Carbopol; (BF Goodrich , Ohio , USA) are particularly
appropriate. They are cross - linked with an allyl sucrose or
with allyl pentaerythritol. Among then , there may be mentioned Carbopol 974P , 934P and 971P. Among the copolymers of maleic anhydride and alkenyl derivative, the copolymers EMA (Monsanto ) which are copolymers of maleic
anhydride and ethylene. The dissolution of these polymers in
water leads to an acid solution that will be neutralized ,
preferably to physiological pH , in order to give the adjuvant
solution into which the immunogenic , immunological or
vaccine composition itself will be incorporated .
Further suitable adjuvants include , but are not limited to ,
the RIBI adjuvant system ( Ribi Inc.), Block co - polymer
( CytRx, Atlanta , Ga . ) , SAF - M ( Chiron, Emeryville, Calif. ),
monophosphoryl lipid A , Avridine lipid - amine adjuvant,
heat - labile enterotoxin from E. coli ( recombinant or otherwise ) , cholera toxin , IMS 1314 or muramyl dipeptide among
many others.
Preferably, the adjuvant is added in an amount of about
100 ug to about 10 mg per dose . Even more preferably, the
adjuvant is added in an amount of about 100 ug to about 10
mg per dose . Even more preferably, the adjuvant is added in
an amount of about 500 ug to about 5 mg per dose . Even
more preferably, the adjuvant is added in an amount of about
750 ug to about 2.5 mg per dose . Most preferably, the
adjuvant is added in an amount of about 1 mg per dose .
In another aspect of the present disclosure, a method for
preparing an immunogenic composition, such as a vaccine,
for invoking an immune response against HEF IDV comprises the steps of 1 ) expressing and recovering HEF IDV
protein , and 2 ) admixing the recovered protein with a
suitable adjuvant. Preferably, the expressing step 1 ) includes
the steps as described for the preparation and recovery of
HEF IDV protein . Another optional step for this method
includes cloning the amplified HEF IDV DNA into a first
vector, excising the DNA from this first vector, and using
this excised HEF IDV DNA for cloning into the transfer
vector. Preferably, the recovery step of this method also
includes the step of separating the media from the cells and
cell debris. This can be done in any conventional manner,

80% ( v / v ), still more preferably about 70 % ( v / v ). Optionally,
this method can also include the addition of a protectant. A
protectant as used herein , refers to an anti -microbiological

active agent, such as for example Gentamycin , Merthiolate,
5 and the like . In particular adding a protectant is most
preferred for the preparation of a multi -dose composition .
Those anti-microbiological active agents are added in con
centrations effective to prevent the composition of interest
from any microbiological contamination or for inhibition of
10 any microbiological growth within the composition of inter
est .
The methods and compositions of the present disclosure

15

20
25

30
35

40

can also comprise the addition of any stabilizing agent, such
as for example saccharides , trehalose, mannitol, saccharose
and the like , to increase and / or maintain product shelf - life
and /or to enhance stability.
In another aspect of the present disclosure , products
resulting from the methods as described above are provided.
In particular, the present disclosure relates to a composition
of matter comprising recombinantly expressed HEF IDV
protein . In some preferred forms, this composition of matter
also comprises an agent suitable for the inactivation of viral
vectors . Such products are useful as immunogenic compo
sitions that induce an immune response and, more prefer
ably, confers protective immunity against the clinical signs
of HEF IDV infection . The composition generally comprises
the polypeptide, or a fragment thereof, expressed by HEF as
the antigenic component of the composition . Of course, it is
understood that the HEF IDV polypeptide used in an immu
nogenic composition in accordance with the present disclo
sure can be derived in any fashion including isolation and
purification, standard protein synthesis, and recombinant
methodology
Clinical signs of IDV infection are generally mild respi
ratory symptoms, but also include contribution to bovine
respiratory disease and bovine respiratory disease complex.
Additionally, viral load , antibody titers , apoptosis of cells ,
programmed cell death , and RNA load in tissues and cells
(including epithelial and non -epithelial cells ) from the as
trachea, lung , nasal septum , nasal turbinates, bronchioles,
and alveoli are also clinical signs of infection .
“ Sequence Identity ” as it is known in the art refers to a

with one preferred manner comprising filtering the cells , cell relationship between two or more polypeptide sequences or
debris, and growth media through a filter having pores two or more polynucleotide sequences, namely a reference
ranging in size from about 0.45 uM to about 1.0 uM . Finally, 45 sequence and a given sequence to be compared with the
for this aspect , it is preferred to include a virus inactivation reference sequence . Sequence identity is determined by
step prior to combining the recovered recombinant HEF comparing the given sequence to the reference sequence
IDV protein in a composition. When an inactivation step is after the sequences have been optimally aligned to produce
included , it is also preferred to include a neutralization step , the highest degree of sequence similarity, as determined by
50 the match between strings of such sequences. Upon such
as described above.
Additionally, the composition can include one or more alignment, sequence identity is ascertained on a position
pharmaceutical-acceptable or veterinary-acceptable carriers. by - position basis , e.g. , the sequences are “ identical ” at a

As used herein , “ a pharmaceutical -acceptable carrier " or particular position if at that position , the nucleotides or
" veterinary - acceptable carrier " includes any and all sol- amino acid residues are identical. The total number of such
vents
, dispersion media, coatings, stabilizing agents, 55 position identities is then divided by the total number of
diluents , preservatives, antibacterial and antifungal agents, nucleotides or residues in the reference sequence to give %
isotonic agents, adsorption delaying agents, and the like . In sequence identity . Sequence identity can be readily calcu
one preferred form , the composition provided herewith , lated by known methods, including but not limited to , those
contains HEF IDV protein recovered from in vitro cultured described in Computational Molecular Biology, Lesk , A. N. ,
cells , wherein said cells were infected with a recombinant 60 ed . , Oxford University Press, New York ( 1988 ) , Biocom
viral vector containing HEF IDV DNA and expressing HEF puting: Informatics and Genome Projects, Smith, D. W., ed . ,
IDV protein , and wherein the cell culture was treated to Academic Press , New York ( 1993 ) ; Computer Analysis of
inactivate the viral vector, and an equivalent concentration Sequence Data , Part I , Griffin, A. M. , and Griffin , H. G. , eds . ,
of a neutralization agent was added, and wherein both an Humana Press, New Jersey ( 1994 ) ; Sequence Analysis in
adjuvant and physiological saline are also added. When 65 Molecular Biology , von Heinge, G. , Academic Press ( 1987 ) ;
included , the amount of physiological saline is preferably Sequence Analysis Primer, Gribskov, M. and Devereux , J. ,
about 50 to about 90 % ( v / v ), more preferably about 60 to eds . , M. Stockton Press, New York ( 1991 ) ; and Carillo , H. ,
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and Lipman, D. , SIAM J. Applied Math ., 48 : 1073 ( 1988 ) ,
the teachings of which are incorporated herein by reference .
Preferred methods to determine the sequence identity are

10

substitutions . However, conservative substitutions are not
included as a match when determining sequence identity.
“ Sequence homology ” , as used herein , refers to a method
designed to give the largest match between the sequences of determining the relatedness of two sequences . To deter
tested. Methods to determine sequence identity are codified 5 mine sequence homology, two or more sequences are opti
in publicly available computer programs which determine mally aligned, and gaps are introduced if necessary. How
sequence identity between given sequences. Examples of ever, in contrast to " sequence identity ”, conservative amino
such programs include, but are not limited to , the GCG acid substitutions are counted as a match when determining
program package (Devereux , J. , et al . , Nucleic Acids sequence homology. In other words, to obtain a polypeptide
Research , 12 ( 1 ) : 387 ( 1984 ) ) , BLASTP, BLASTN and 10 or polynucleotide having 95 % sequence homology with a
FASTA ( Altschul, S. F. et al . , J. Molec . Biol . , 215 : 403-410 reference sequence , 85 % , preferably 90 % , even more pref
( 1990) . The BLASTX program is publicly available from erably 95 % of the amino acid residues or nucleotides in the
NCBI and other sources (BLAST Manual, Altschul, S. et al . , reference sequence must match or comprise a conservative
NCVI NLM NIH Bethesda, Md . 20894 , Altschul, S. F. et al . , substitution with another amino acid or nucleotide, or a
J. Molec . Biol . , 215 : 403-410 ( 1990 ) , the teachings of which 15 number of amino acids or nucleotides up to 15 % , preferably
are incorporated herein by reference ). These programs opti- up to 10 % , even more preferably up to 5 % of the total amino

mally align sequences using default gap weights in order to acid residues or nucleotides, not including conservative
produce the highest level of sequence identity between the substitutions, in the reference sequence may be inserted into
given and reference sequences. As an illustration , by a the reference sequence . Preferably the homologous
polynucleotide having a nucleotide sequence having at least , 20 sequence comprises at least a stretch of 50 , even more
for example, 85 % , preferably 90% , even more preferably preferably 100 , even more preferably 250 , even more pref
95 % “ sequence identity ” to a reference nucleotide sequence, erably 500 nucleotides.
it is intended that the nucleotide sequence of the given
polynucleotide is identical to the reference sequence except

A “ conservative substitution ” refers to the substitution of
an amino acid residue or nucleotide with another amino acid

mutations of the reference sequence may occur at the 5 ' or
3 ' terminal positions of the reference nucleotide sequence or

vided in the immunological composition at an antigen
inclusion level effective for inducing the desired immune

that the given polynucleotide sequence may include up to 25 residue or nucleotide having similar characteristics or prop
15 , preferably up to 10 , even more preferably up to 5 point erties including size , hydrophobicity, etc. , such that the
mutations per each 100 nucleotides of the reference nucleo- overall functionality does not change significantly.
tide sequence. In other words, in a polynucleotide having a
Isolated ” means altered " by the hand of man ” from its
nucleotide sequence having at least 85 % , preferably 90 % , natural state , i.e. , if it occurs in nature, it has been changed
even more preferably 95 % identity relative to the reference 30 or removed from its original environment, or both . For
nucleotide sequence, up to 15 % , preferably 10 % , even more example , a polynucleotide or polypeptide naturally present
preferably 5 % of the nucleotides in the reference sequence in a living organism is not “ isolated ,” but the same poly
or a
nucleotide or polypeptide separated from the coexisting
may be deleted or substituted with another nucle
number of nucleotides up to 15 % , preferably 10 % , even materials of its natural state is “ isolated ” , as the term is
more preferably 5 % of the total nucleotides in the reference 35 employed herein .
sequence may be inserted into the reference sequence . These
According to a further aspect , HEF IDV protein is pro
anywhere between those terminal positions , interspersed
either individually among nucleotides in the reference
sequence or in one or more contiguous groups within the
reference sequence . Analogously, by a polypeptide having a
given amino acid sequence having at least , for example ,
85 % , preferably 90 % , even more preferably 95 % sequence
identity to a reference amino acid sequence, it is intended
that the given amino acid sequence of the polypeptide is
identical to the reference sequence except that the given
polypeptide sequence may include up to 15 , preferably up to
10 , even more preferably up to 5 amino acid alterations per
each 100 amino acids of the reference amino acid sequence .
In other words, to obtain a given polypeptide sequence
having at least 85 % , preferably 90 % , even more preferably
95 % sequence identity with a reference amino acid
sequence, up to 15 % , preferably up to 10% , even more
preferably up to 5 % of the amino acid residues in the
reference sequence may be deleted or substituted with
another amino acid , or a number of amino acids up to 15 % ,

response , namely reducing the incidence of or lessening the
40 severity of clinical signs resulting from IDV infection .
Preferably, the HEF IDV protein inclusion level is at least
0.2 ug antigen /ml of the final immunogenic composition
( ug /ml ), more preferably from about 0.2 to about 400 ug /ml.
The polypeptide is incorporated into a composition that
45 can be administered to an animal susceptible to IDV infec
tion . In preferred forms, the composition may also include
additional components known to those of skill in the art ( see
also Remington's Pharmaceutical Sciences . ( 1990) . 18th ed .
Mack Publ., Easton ).
50 Those of skill in the art will understand that the compo
sition herein may incorporate known injectable, physiologi
cally acceptable, sterile solutions . For preparing a ready -to
use solution for parenteral injection or infusion, aqueous
isotonic solutions , such as e.g. saline or corresponding
55 plasma protein solutions are readily available. In addition,
the immunogenic and vaccine compositions of the present
disclosure can include diluents, isotonic agents, stabilizers ,

preferably up to 10 % , even more preferably up to 5 % of the or adjuvants . Diluents can include water, saline , dextrose ,
total number of amino acid residues in the reference ethanol, glycerol, and the like . Isotonic agents can include
sequence may be inserted into the reference sequence. These 60 sodium chloride, dextrose, mannitol, sorbitol, and lactose ,
alterations of the reference sequence may occur at the amino among others . Stabilizers include albumin and alkali salts of
or the carboxy terminal positions of the reference amino acid ethylendiamintetracetic acid , among others. Suitable adju
sequence or anywhere between those terminal positions , vants , are those described above .

interspersed either individually among residues in the refAccording to a further aspect , the immunogenic compo
erence sequence or in the one or more contiguous groups 65 sition of the present disclosure further comprises a pharma

within the reference sequence . Preferably, residue positions
which are not identical differ by conservative amino acid

ceutical acceptable salt , preferably a phosphate salt in physi
ologically acceptable concentrations. Preferably, the pH of
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said immunogenic composition is adjusted to a physiological pH , meaning between about 6.5 and 7.5 .

ister the immune stimulant in a suitable dose . The kit may
also comprise a second container, including at least one dose

The immunogenic compositions described herein can

of the immune stimulant.

further include one or more other immunomodulatory agents
A further aspect of the present disclosure relates to the kit
such as , e . g . , interleukins, interferons , or other cytokines . 5 as described above , comprising the immunogenic composi

The immunogenic compositions can also include Gentamicin and Merthiolate . In another preferred embodiment, the

present disclosure contemplates vaccine compositions comprising from about 1 ug /ml to about 60 ug /ml of antibiotics,
and more preferably less than about 30 ug /ml of antibiotics.
It will be found that the immunogenic compositions
comprising recombinant HEF IDV protein as provided herewith are very effective in reducing the severity of or incidence of clinical signs associated with IDV infections up to
and including the prevention of such signs.
Another aspect of the present disclosure relates to a kit .
Generally the kit includes a container comprising at least
one dose of the immunogenic composition of HEF IDV
nucleotide sequence or protein as provided herewith ,
wherein one dose comprises at least 100 ug/kg of the animal
weight of the plasmid containing the HEF IDV nucleotide
sequence or 2 ug HEF IDV protein . Said container can
comprise from 1 to 250 doses of the immunogenic composition . In some preferred forms, the container contains 1 , 10 ,
25 , 50 , 100 , 150 , 200 , or 250 doses of the immunogenic
composition of HEF IDV plasmid or protein . Preferably,
each of the containers comprising more than one dose of the
immunogenic composition of HEF IDV plasmid or protein
further comprises an anti-microbiological active agent.
Those agents are for example , antibiotics including Gentamicin and Merthiolate and the like. Thus, one aspect of the
present disclosure relates to a container that comprises from
1 to 250 doses of the immunogenic composition of HEF IDV
plasmid or protein , wherein one dose comprises at least 100
ug /kg of the animal weight of the plasmid containing the
HEF IDV nucleotide sequence or 2 ug HEF IDV protein , and
Gentamicin and / or Merthiolate, preferably from about 1
ug /ml to about 60 ug /ml of antibiotics, and more preferably
less than about 30 ug /ml. In preferred forms, the kit also

tion of HEF IDV as provided herewith and the instruction
manual, wherein the instruction manual further includes the
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information to administer the HEF IDV immunogenic com
position together, or around the same time as , with an
immunogenic composition that comprises an additional anti
gen effective for reducing the severity of or incidence of
clinical signs related to another cattle or porcine pathogen .
Preferably, the manual contains the information of when the
HEF IDV containing composition and the immunogenic
composition that comprises an additional antigen are admin
istered .
A further aspect , relates to the use of any of the compo
sitions provided herewith as a medicament, preferably as a
veterinary medicament, even more preferably as a vaccine .
Moreover, the present disclosure also relates to the use of
any of the compositions described herein , for the preparation
of a medicament for lessening the severity or incidence of
clinical symptoms associated with IDV infection. Prefer
ably, the medicament is for the prevention of IDV infection
in cattle or swine .
A further aspect relates to a method for ( 1 ) the prevention
of an infection, or re - infection with IDV or (2 ) the reduction
in incidence or severity of or elimination of clinical signs or

symptoms caused by IDV in a subject, comprising admin
30 istering any of the immunogenic compositions provided
herewith to a subject in need thereof. Preferably, the subject
is a cow or pig . It is understood that the reduction is in
comparison to a subject that has not received an adminis
tration of a composition of the present disclosure . Prefer
35 ably, one dose or two doses of the immunogenic composi
tion is / are administered, wherein one dose preferably
comprises at least about 100 ug /kg of the animal weight of
the plasmid containing the HEF IDV nucleotide sequence or

2 ug HEF IDV protein . A further aspect relates to the method
includes an instruction manual, including the information 40 of treatment as described above , wherein a second applica
for the administration of at least one dose of the immuno- tion of the immunogenic composition is administered . Pref

genic composition of HEF IDV plasmid protein into animals , preferably cattle or pigs to lessen the incidence and / or
severity of clinical symptoms associated with HEF IDV
infection . Moreover, according to a further aspect , said
instruction manual comprises the information of a second or
further administration ( s) of at least one dose of the immunogenic composition of HEF IDV plasmid or protein ,
wherein the second administration or any further administration is at least 14 days beyond the initial or any former
administration . In some preferred forms, said instruction
manual also includes the information , to administer an
immune stimulant. Preferably, said immune stimulant shall
be given at least twice. Preferably, at least 3 , more preferably
at least 5 , and even more preferably at least 7 days are
between the first and the second or any further administration of the immune stimulant. Preferably, the immune stimulant is given at least 10 days , preferably 15 , even more
preferably 20 , and still even more preferably at least 22 days
beyond the initial administration of the immunogenic composition of HEF IDV plasmid or protein . It is understood that
any immune stimulant known to a person skilled in the art
can also be used . “ Immune stimulant ” as used herein , means
any agent or composition that can trigger a general immune
response , preferably without initiating or increasing a specific immune response , for example the immune response
against a specific pathogen . It is further instructed to admin-

45

50

55

60
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erably, the second administration is done with the same
immunogenic composition, preferably having the same
amount of HEF IDV protein . Preferably, the second admin
istration is done at least 14 days beyond the initial admin
istration , even more preferably at least 4 weeks beyond the
initial administration . In preferred forms, the method is
effective after just a single dose of the immunogenic com
position and does not require a second or subsequent admin
istration in order to confer the protective benefits upon the
subject.
According to a further aspect , the present disclosure
provides a multivalent combination vaccine which includes
an immunological agent effective for reducing the incidence
of or lessening the severity of IDV infection, and at least one
immunological active component against another disease
causing organism in swine or cattle .
In particular the immunological agent effective for reduc
ing the incidence of or lessening the severity of IDV
infection is an IDV antigen . Preferably, said IDV antigen is
a HEF IDV plasmid or protein as provided herewith , or any
immunogenic composition as described above , that com
prises HEF IDV plasmid or protein .
The terms “ immunogenic protein ”, “ immunogenic poly
peptide” or “ immunogenic amino acid sequence ” as used
herein refer to any amino acid sequence which elicits an
immune response in a host against a pathogen comprising
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said immunogenic protein, immunogenic polypeptide or

immunogenic amino acid sequence. An " immunogenic protein ” , “ immunogenic polypeptide” or “ immunogenic amino
acid sequence" as used herein , includes the full- length
sequence of any proteins , analogs thereof, or immunogenic
fragments thereof. By “ immunogenic fragment” is meant a
fragment of a protein which includes one or more epitopes
and thus elicits the immunological response against the
relevant pathogen . Such fragments can be identified using
any number of epitope mapping techniques, well known in
the art. See , e.g. , Epitope Mapping Protocols in Methods in
Molecular Biology , Vol. 66 (Glenn E. Morris, Ed . , 1996 )
Humana Press , Totowa, New Jersey. For example, linear
epitopes may be determined by e.g. , concurrently synthe
sizing large numbers of peptides on solid supports, the
peptides corresponding to portions of the protein molecule ,
and reacting the peptides with antibodies while the peptides
are still attached to the supports . Such techniques are known
in the art and described in , e.g. , U.S. Pat. No. 4,708,871 ;
Geysen et al . ( 1984 ) Proc . Natl . Acad . Sci . USA 81 : 39984002 ; Geysen et al . ( 1986 ) Molec . Immunol. 23 : 709-715 .
Similarly, conformational epitopes are readily identified by
determining spatial conformation of amino acids such as by,
e.g. , x - ray crystallography and 2 - dimensional nuclear magnetic resonance . See , e.g. , Epitope Mapping Protocols,
supra . Synthetic antigens are also included within the defi
nition, for example, polyepitopes , flanking epitopes, and
other recombinant or synthetically derived antigens. See ,
e.g. , Bergmann et al . ( 1993 ) Eur. J. Immunol. 23 : 2777-2781 ;
Bergmann et al . ( 1996 ) , J. Immunol. 157 : 3242-3249 ; Suhrbier, A. ( 1997 ) , Immunol. and Cell Biol . 75 : 402-408 ; Gard
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preferred embodiment, the immunological active compo

nent is an attenuated microorganism , including modified live
virus (MLV ), a killed -microorganism or at least an immu
nological active part of a microorganism .
5 “ Immunological active part of a microorganism ” as used

herein means a protein-, sugar- , and or glycoprotein con
taining fraction of a microorganism that comprises at least
one antigen that induces or stimulates the immune response

in an animal to which said component is administered .
10 According
to a preferred embodiment, said immune

response is directed to said immunological active part of a
microorganism or to a microorganism comprising said
immunological active part.
15 The present disclosure also relates to vaccines comprising
a nucleotide sequence of HEF IDV, or a homologue or
fragment thereof, and an acceptable pharmaceutical or vet

erinary vehicle . In one embodiment of the disclosure , the
nucleotide sequence is selected from , SEQ ID NO . 2 or a
20 homologue or fragment thereof. In another embodiment of
the disclosure , the homologue has at least 85 , 90 , 91 , 92 , 93 ,

94 , 95 , 96 , 97 , 98 , 99 , 99.5 , or 100 % sequence identity to
SEQ ID NO . 2. In yet another embodiment, the vaccine

25

further comprises an adjuvant.

A further aspect of the present disclosure relates to

vaccines comprising a vector and an acceptable pharmaceu
tical or veterinary vehicle , the vector comprising a nucleo
tide sequence of HEF IDV, preferably SEQ ID NO . 2 , or a
homologue or fragment thereof.
30 Additionally, the present disclosure relates to methods of

immunizing a mammal against IDV comprising administer

ner et al . , ( 1998 ) 12th World AIDS Conference, Geneva ,
Switzerland, Jun . 28 - Jul . 3 , 1998 .
Preferably the other disease -causing organism in swine is

ing to a mammal an effective amount of a vaccine or

sonia intracellularis , Leptospira spp .; preferably Leptospira

c ) , d ) or e ) .

immunogenic composition described above .
The present disclosure likewise relates to nucleotide
selected from the group consisting of: Actinobacillus pleu- 35 sequences
, characterized in that they are selected from : a ) a
ropneumonia ; Adenovirus; Alphavirus such as Eastern nucleotide
sequence of SEQ ID NO . 2 ; b ) a nucleotide
equine encephalomyelitis viruses ; Bordetella bronchisep
tica ; Brachyspira spp . , preferably B. hyodyentheriae; B. sequence homologous to a nucleotide sequence such as
piosicoli , Brucella suis , preferably biovars 1 , 2 , and 3 ; defined in a ) ; c ) a nucleotide sequence complementary to a
Classical swine fever virus; Clostridium spp . , preferably Cl. 40 nucleotide sequence such as defined in a) or b ) , and a
difficile, Cl. perfringens types A , B , and C , Cl. novyi, nucleotide sequence of their corresponding RNA ; d) a
Cisepticum , Cl . tetani; Coronavirus, preferably Porcine nucleotide sequence capable of hybridizing under stringent
Respiratory Corona virus; Eperythrozoonosis suis; Erysip- conditions with a sequence such as defined in a ) , b ) or c ) ; e )
elothrix rhsiopathiae ; Escherichia coli ; Haemophilus para- a nucleotide sequence comprising a sequence such as
suis , preferably subtypes 1 , 7 and 14 : Hemagglutinating 45 defined in a) , b ) , c ) or d) ; and f) a nucleotide sequence
encephalomyelitis virus; Japanese Encephalitis Virus; Law- modified by a nucleotide sequence such as defined in a ) , b ) ,

australis ; Leptospira canicola ; Leptospira grippotyphosa ;
Leptospira icterohaemorrhagicae; and Leptospira interro-

Nucleotide, polynucleotide or nucleic acid sequence will
be understood according to the present disclosure as mean

gans; Leptospira pomona; Leptospira tarassovi; Mycobac- 50 ing both a double -stranded or single - stranded DNA in the
terium spp . preferably M. avium ; M. intracellulare ; and M.
bovis; Mycoplasma hyopneumoniae (M. hyo ); Pasteurella

monomeric and dimeric ( so - called in tandem ) forms and the
transcription products of said DNAs.
multocida ; Porcine cytomegalovirus; Porcine Parvovirus;
Complementary nucleotide sequence of a sequence of the
Porcine Reproductive and Respiratory Syndrome ( PRRS ) disclosure is understood as meaning any DNA whose
Virus; Pseudorabies virus; Rotavirus; Salmonella spp .; pref- 55 nucleotides are complementary to those of the sequence of
erably S. thyhimurium ; and S. choleraesuis ; Staph . hyicus; the disclosure, and whose orientation is reversed ( antipar
Staphylococcus spp . preferably Streptococcus spp . , prefer- allel sequence ).
ably Strep. suis ; Swine herpes virus; Swine Influenza Virus;
Hybridization under conditions of stringency with a
Swine pox virus; Swine pox virus; Vesicular stomatitis nucleotide sequence according to the disclosure is under
virus; Virus of vesicular exanthema of swine ; Leptospira 60 stood as meaning a hybridization under conditions of tem
Hardjo ; and /or Mycoplasma hyosynoviae.
perature and ionic strength chosen in such a way that they
An “ immunological active component” as used herein allow the maintenance of the hybridization between two
means a component that induces or stimulates the immune fragments of complementary DNA .
response in an animal to which said component is adminAmong the nucleotide sequences according to the disclo
istered . According to a preferred embodiment, said immune 65 sure , those are likewise preferred which can be used as a
response is directed to said component or to a microorgan- primer or probe in methods allowing the homologous
ism comprising said component. According to a further sequences according to the disclosure to be obtained, these
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methods, such as the polymerase chain reaction (PCR ), described by Kievitis et al . in 1991 ; the SDA technique
nucleic acid cloning and sequencing, being well known to ( Strand Displacement Amplification ) (Walker et al . , 1992 ) ;
the TMA technique ( Transcription Mediated Amplification ).
the person skilled in the art.
Among said nucleotide sequences according to the disThe polynucleotides of the disclosure can also be
closure , those are again preferred which can be used as a 5 employed in techniques of amplification or of modification
primer or probe in methods allowing the presence of IDV or of the nucleic acid serving as a probe, such as : the LCR
one of its variants such as defined below to be diagnosed . technique (Ligase Chain Reaction) , described by Landegren
Modified nucleotide sequence will be understood as et al . in 1988 and improved by Barany et al . in 1991 , which
meaning any nucleotide sequence obtained by mutagenesis employs a thermostable ligase ; the RCR technique (Repair
according to techniques well known to the person skilled in 10 Chain Reaction ), described by Segev in 1992 ; the CPR
the art, and containing modifications with respect to the technique ( Cycling Probe Reaction) , described by Duck et
15

normal sequences according to the disclosure, for example al . in 1990 ; the amplification technique with Q -beta repli
mutations in the regulatory and / or promoter sequences of case , described by Miele et al . in 1983 and especially
polypeptide expression, especially leading to a modification improved by Chu et al . in 1986 , Lizardi et al . in 1988 , then
of the rate of expression of said polypeptide or to a modu- 15 by Burg et al . as well as by Stone et al . in 1996 .
lation of the replicative cycle .
The disclosure likewise relates to a pharmaceutical com
Modified nucleotide sequence will likewise be understood position comprising a compound selected from the follow
as meaning any nucleotide sequence coding for a modified ing compounds: a ) a nucleotide sequence according to the
polypeptide such as defined below .
disclosure ; b ) a polypeptide according to the disclosure ; or
In the present description, the terms polypeptide, peptide 20 c ) a vector transformed according to the disclosure; possibly
and protein are interchangeable.
in combination with a pharmaceutically acceptable carrier
In the case of a substitution , one or more consecutive or and, if need be , with one or more adjuvants of the appro
nonconsecutive amino acids are replaced by " equivalent ” priate immunity.
amino acids . The expression “ equivalent ” amino acid is
The disclosure also relates to an immunogenic and / or
directed here at designating any amino acid capable of being 25 vaccine composition, characterized in that it comprises a
substituted by one of the amino acids of the base structure compound selected from the following compounds: a ) a
without, however, essentially modifying the biological nucleotide sequence according to the disclosure ; b ) a poly
activities of the corresponding peptides and such that they peptide according to the disclosure ; or c ) a vector according
will be defined by the following. These equivalent amino to the disclosure .
acids can be determined either by depending on their struc- 30 The disclosure is likewise directed at a pharmaceutical
tural homology with the amino acids which they substitute, composition according to the disclosure , for the prevention
or on results of comparative tests of biological activity or the treatment of an infection by IDV .
between the different polypeptides , which are capable of
It is understood that “ prevention ” as used in the present

being carried out . By way of example, the possibilities of disclosure, includes the complete prevention of infection by
substitutions capable of being carried out without resulting 35 a HEF IDV, but also encompasses a reduction in the severity

in an extensive modification of the biological activity of the of or incidence of clinical signs associated with or caused by
corresponding modified polypeptides will be mentioned , the IDV infection . Such prevention is also referred to herein as
replacement, for example, of leucine by valine or isoleucine , a protective effect.
of aspartic acid by glutamic acid , of glutamine by asparaThe disclosure likewise concerns the use of a composition
gine , of arginine by lysine etc., the reverse substitutions 40 according to the disclosure, for the preparation of a medi
naturally being envisageable under the same conditions .
cament intended for the prevention or the treatment of
The disclosure likewise relates to nucleotide sequences infection by IDV .
utilizable as a primer or probe, characterized in that said
The compositions according to the disclosure will contain
sequences are selected from the nucleotide sequences an effective quantity of the compounds of the disclosure , that
according to the disclosure.
45 is to say in sufficient quantity of said compound ( s) allowing
The disclosure additionally relates to the use of a nucleo- the desired effect to be obtained . The person skilled in the art
tide sequence according to the disclosure as a primer or will know how to determine this quantity, as a function , for
probe for the detection and / or the amplification of nucleic example , of the age and of the weight of the individual to be
acid sequences.
treated , of the state of advancement of the pathology, of the
The nucleotide sequences according to the disclosure can 50 possible secondary effects and by means of a test of evalu
thus be used to amplify nucleotide sequences , especially by ation of the effects obtained on a population range, these
the PCR technique ( polymerase chain reaction) (Erlich,
1989 ; Innis et al . , 1990 ; Rolfs et al . , 1991 ; and White et al . ,

tests being known in these fields of application .
According to the disclosure , said vaccine combinations

cation ), described by Guatelli et al . in 1990 ; the NASBA
technique (Nucleic Acid Sequence Based Amplification ),

muscular, intradermal or subcutaneous route , or by the oral
or nasal route . In some embodiments , the vaccine compo

1997 ) . These oligodeoxyribonucleotide or oligoribonucle- will preferably be combined with a pharmaceutically or
otide primers advantageously have a length of at least 8 55 veterinary acceptable carrier and , if need be , with one or
nucleotides , preferably of at least 12 nucleotides, and even more adjuvants of the appropriate immunity.
more preferentially at least 20 nucleotides. Other amplifiVaccines and immunogenic compositions according to the
cation techniques of the target nucleic acid can be advanta- disclosure can likewise be prepared in the form of a com
geously employed as alternatives to PCR .
position containing a vector according to the disclosure,
The nucleotide sequences of the disclosure, in particular 60 placed under the control of regulation elements allowing its
the primers according to the disclosure , can likewise be expression in man or animal . Such a vaccine will advanta
employed in other procedures of amplification of a target geously comprise, apart from the recombinant vector, a
nucleic acid, such as : the TAS technique ( Transcription- saline solution, for example a sodium chloride solution .
based Amplification System) , described by Kwoh et al . in
These compounds can be administered by the systemic
1989 ; the 3SR technique ( Self -Sustained Sequence Repli- 65 route, in particular by the intravenous route , by the intra
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sition comprising plasmids or polypeptides according to the
disclosure will be administered by injection or intranasally,
through the food, or by nebulization once or several times ,

glycol , can be used to increase the solubility of the ingre
dients in the formulation and the stability of the liquid

preparation . Further additives that can be employed in the
present vaccine include, but are not limited to , dextrose ,

staggered over time.

Their administration modes , dosages and optimum phar- 5 conventional antioxidants and conventional chelating agents

maceutical forms can be determined according to the criteria such as ethylenediamine tetraacetic acid (EDTA ). Parenteral
generally taken into account in the establishment of a dosage forms must also be sterilized prior to use .
treatment adapted to an animal such as , for example, the age
It should be appreciated that all scientific and technologi
or the weight, the seriousness of its general condition, the cal terms used herein have the same meaning as commonly
tolerance to the treatment and the secondary effects noted . 10 understood by those of ordinary skill in the art.
Preferably, the vaccine of the present disclosure is admin
Another aspect of the present disclosure is the preparation
istered in an amount that is protective or provides a protec- of the combination vaccine ( s) or immunogenic composi
tive effect against IDV infection .
tions . Such combinations can be between the different
Another preferred vaccine of the present disclosure uti- vaccine components described herein . For example, a vac
lizes suitable plasmids for delivering the HEF IDV nucleo- 15 cine of the present disclosure can include both protein
tide sequence to an animal in need thereof including to cattle portions and DNA portions of HEF IDV, as described herein ,
or pigs . In contrast to the traditional vaccine that uses live or which are administered concurrently or separately . Addi
killed cell culture propagated whole virus, this disclosure tionally, the combinations can be between the HEF IDV
provides for the direct inoculation of cattle or pigs with the vaccine components described herein and antigens of other
plasmid DNA containing the HEF IDV nucleotide sequence. 20 disease -causing organisms, such as those described above .
The vaccine can be administered in a single dose or in
According to a further aspect , the vaccine or immuno
repeated doses with single doses being preferred. Single genic composition is first dehydrated. If the composition is
dose vaccines provide protection after a single dose without first lyophilized or dehydrated by other methods, then , prior
the need for any booster or subsequent dosages. Protection to vaccination, said composition is rehydrated in aqueous

can include the complete prevention of clinical signs of 25 (e.g. saline, PBS (phosphate buffered saline ) or non -aque
infection , or a lessening of the severity, duration , or likeli- ous solutions (e.g. oil emulsion (mineral oil , or vegetable/

hood of the manifestation of one or more clinical signs of
infection . Dosages may range , for example , from about 1
microgram to about 1,000 micrograms/kg of the animal of
the plasmid DNA containing the HEF IDV sequence, preferably 100 to 200 micrograms/kg of the animal of the HEF
IDV DNA . Methods are known in the art for determining or
titrating suitable dosages of active antigenic agent to find
minimal effective dosages based on the weight of the animal,
concentration of the antigen and other typical factors. Preferably, the HEF IDV DNA is used as a vaccine .
Desirably , the vaccine is administered to an animal not yet
exposed to IDV.
When administered as a liquid , the present vaccine may
be prepared in the form of an aqueous solution , syrup , an
elixir, a tincture and the like . Such formulations are known
in the art and are typically prepared by dissolution of the
antigen and other typical additives in the appropriate carrier
or solvent systems . Suitable carriers or solvents include , but
are not limited to , water, saline , ethanol, ethylene glycol ,
glycerol, etc. Typical additives are , for example, certified
dyes, flavors , sweeteners and antimicrobial preservatives
such as thimerosal ( sodium ethylmercurithiosalicylate ).
Such solutions may be stabilized, for example, by addition
of partially hydrolyzed gelatin, sorbitol or cell culture
medium , and may be buffered by conventional methods
using reagents known in the art, such as sodium hydrogen
phosphate , sodium dihydrogen phosphate , potassium hydrogen phosphate , potassium dihydrogen phosphate , a mixture
thereof, and the like .
Liquid formulations also may include suspensions and
emulsions that contain suspending or emulsifying agents in
combination with other standard co - formulants . These types
of liquid formulations may be prepared by conventional
methods. Suspensions , for example, may be prepared using
a colloid mill. Emulsions, for example, may be prepared
using a homogenizer.
Parenteral formulations, designed for injection into body
fluid systems, require proper isotonicity and pH buffering to
the corresponding levels of body fluids. Isotonicity can be
appropriately adjusted with sodium chloride and other salts
as needed . Suitable solvents, such as ethanol or propylene

metabolizable oil based / single or double emulsion based ),
aluminum - based , carbomer based adjuvant).
According to the present disclosure , an effective amount
30 of a combination vaccine administered to an animal in need
thereof provides effective immunity or a protective effect
against microbiological infections caused by IDV and at
least one further pathogen. Preferred combinations of anti
gens for the treatment and prophylaxis of microbiological
35 diseases in cattle and pigs are listed above .
BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specifi
aspects of the present disclosure. The disclosure may be
better understood by reference to one or more of these
drawings in combination with the detailed description of
specific embodiments presented herein .
FIG . 1 is a depiction of the phylogenetic analysis of
ConD -HEF protein ;
FIG . 2A is a graph illustrating HI antibody responses in
peripheral blood induced by ConD -HEF vaccine and evalu
ated by hemagglutination inhibition (HI ) assay;
FIG . 2B is a graph illustrating HI antibody responses in
peripheral blood induced by the second ConD - HEF vaccine
group and evaluated by hemagglutination inhibition (HI)
assay ;
FIG . 2C is a graph illustrating the mean HI antibody titers
of the two vaccine groups at 3 weeks post final vaccination .
FIG . 2D is a graph illustrating the relative HI titers that
were calculated by normalizing D/ 660 HI titer to D/OK HI
titer for each individual animal.
FIG . 2E provides depictions of the hemagglutinin -es
terase - fusion protein ( HEFP) structure of influenza D virus
( PDB ID 5e64 ) ;
FIG . 3 is a graph illustrating IDV RNA load in lung
tissues quantified using qRT - PCR ;
FIG . 4A is a photograph illustrating IDV RNA + cells
( black silver grains in radioautographs) in lung tissues
detected using in situ hybridization from the area in the left

40 cation and are included to further demonstrate certain
45

50

55

60
65

red box in FIG . 4B ;
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FIG . 4B is a photograph illustrating IDV RNA + cells
FIG . 6D is a photograph of immunohistochemically
stained lung epithelial tissue ;
FIG . 6E is a photograph of immunohistochemically
detected using in situ hybridization;
FIG . 4C is a photograph illustrating IDV RNA + cells stained lung epithelial tissue ;
(black silver grains in radioautographs) in lung tissues 5 FIG . 6F is a photograph of immunohistochemically
(black silver grains in radioautographs) in lung tissues

detected using in situ hybridization from the area in the right
FIG . 4D is a photograph illustrating IDV RNA + cells
( black silver grains in radioautographs) in lung tissues
detected using in situ hybridization from the area in the left
red box in FIG . 4E ;
FIG . 4E is a photograph illustrating IDV RNA + cells in
lung tissues detected using in situ hybridization (black silver
grains in radioautographs );
FIG . 4F is a photograph illustrating IDV RNA + cells
( black silver grains in radioautographs) in lung tissues
detected using in situ hybridization from the area in the right
red box in FIG . 4E ;
FIG . 4G is a photograph illustrating IDV RNA + cells
(black silver grains in radioautographs) in lung tissues
detected using in situ hybridization from the area in the left

stained lung epithelial tissue ;
FIG . 7A is a micrograph of lung epithelial cells that
received the IDV D/ 660 vaccine and were challenged intra
nasally with IDV D/ 660 ;
10
FIG . 7B is a micrograph of lung epithelial cells that
received the IDV D/ 660 vaccine and were challenged intra
nasally with IDV D/ 660 ;
FIG . 7C is a micrograph of lung epithelial cells that
15 received a sham vaccine and were challenged intranasally
with IDV D/ 660 ;
FIG . 7D is a micrograph of lung epithelial cells that
received a sham vaccine and were challenged intranasally
with IDV D/ 660 ;
20
FIG . ZE is a micrograph of lung epithelial cells that
received a sham vaccine and were challenged intranasally
with IDV D/ 660 ;
red box in FIG . 4H ;
FIG . 7F is a micrograph of lung epithelial cells that
FIG . 4H is a photograph illustrating IDV RNA + cells in received a sham vaccine and were challenged intranasally
lung tissues detected using in situ hybridization ( black silver 25 with IDV D /660 ;
grains in radioautographs );
FIG . 76 is a micrograph of lung epithelial cells that
FIG . 41 is a photograph illustrating IDV RNA + cells received the IDV D/OK vaccine and were challenged intra
( black silver grains in radioautographs) in lung tissues nasally with IDV DIOK ;
detected using in situ hybridization from the area in the right 30 FIG . 7H is a micrograph of lung epithelial cells that
red box in FIG . 4H ;
received the IDV D/OK vaccine and were challenged intra
FIG . 4J is a photograph illustrating IDV RNA + cells nasally
with IDV DIOK ;
(black silver grains in radioautographs) in lung tissues
FIG . 71 is a micrograph of lung epithelial cells that
detected using in situ hybridization from the area in the left
red box in FIG . 4B ;

received a sham vaccine and were challenged intranasally
D/ OK ;
FIG . 4K is a photograph illustrating IDV RNA + cells in 35 withFIGIDV
.
7J
is a micrograph of lung epithelial cells that
lung tissues detected using in situ hybridization (black silver received a sham
vaccine and were challenged intranasally
grains in radioautographs);
FIG . 4L is a photograph illustrating IDV RNA + cells with IDV D/ OK ;
FIG . 7K is a micrograph of lung epithelial cells that
(black silver grains in radioautographs) in lung tissues
red box in FIG . 4K ;

detected using in situ hybridization from the area in the right 40 received a sham vaccine and were challenged intranasally

red box in FIG . 4K ;

with IDV D/ OK ;

FIG . 5A is a photograph illustrating IDV RNA + cells in
FIG . 7L is a micrograph of lung epithelial cells that
nasal turbinate tissue in the control group detected using in received a sham vaccine and were challenged intranasally
situ hybridization ;
with IDV D/ OK ;
FIG . 5B is a magnified photograph of the area in the red 45
box in FIG . 5A ;

DETAILED DESCRIPTION

FIG . 5C is a photograph illustrating IDV RNA + cells in
tracheal tissue in the control group detected using in situ
The following detailed description and examples set forth
hybridization ;
preferred materials and procedures used in accordance with
FIG . 5D is a magnified photograph of the area in the red 50 the present disclosure. It is to be understood , however, that
box in FIG . 5C ;
this description and these examples are provided by way of
FIG . 5E is a photograph illustrating IDV RNA + cells in illustration only, and nothing therein shall be deemed to be
nasal turbinate tissue in the vaccine group detected using in a limitation upon the overall scope of the present disclosure.
situ hybridization;
It should be appreciated that when typical reaction condi

5F is. 5Ea magnified
photograph of the area in the red
boxFIG
in. FIG
;

55 tions (e.g. , temperature, reaction times, etc.) have been

given , the conditions both above and below the specified
ranges can also be used, though generally less conveniently.
The examples are conducted at room temperature (about 23 °
FIG . 5H is a magnified photograph of the area in the red 60 C. to about 28 ° C.) and at atmospheric pressure unless noted
otherwise . All parts and percents referred to herein are on a
box of FIG . 5G ;
FIG . 6A is a photograph of immunohistochemically weight basis and all temperatures are expressed in degrees
centigrade unless otherwise specified . Further unless noted
stained lung epithelial tissue ;
FIG . 6B is a photograph of immunohistochemically otherwise, all components of the disclosure are understood
65 to be disclosed to cover " comprising” , “ consisting essen
stained lung epithelial tissue ;
FIG . 6C is a photograph of immunohistochemically tially of ” , and “ consisting of ” claim language as those terms
are commonly used in patent claims .
stained lung epithelial tissue ;

FIG . 5G is a photograph illustrating IDV RNA + cells in
tracheal tissue in the vaccine group detected using in situ
hybridization;
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Example 1

nose were kept slightly elevated with respect to the rump for
15 minutes to prevent the inoculum from flowing out of the

Materials and Methods

nostrils .

Animals and Animal Procedures

Body weight and temperature of the guinea pigs were
Guinea pig experiments were conducted by following the 5 monitored
daily for up to 7 days starting from the day of IDV
protocol approved by the Institutional Animal Care and Use challenge but
before virus inoculation ( day 0 ) . At 5 and 7
Committees (IACUC ) at UNL . Twenty - four specific -patho
post challenge, 2 and 4 animals from each group were
gen - free ( SPF ) or viral- antibody - free (VAF ), and approxi days
mately 3 -month - old female guinea pigs of the Dunkin euthanized , respectively. Immediately after euthanasia ,
Hartley strain (Elm Hill Labs , MA , USA ) were used in this 10 blood , nasal turbinate, septum , soft palate, trachea , lung , and
study. The animals were individually housed and were ear draining lymph node were collected . Half of collected
tissues were fixed in 4 % paraformaldehyde (PFA ) and the
tagged after a 1 - week acclimation period.
remaining half were snap frozen immediately in liquid
Consensus DNA Vaccine Design and Preparation
To develop a vaccine that could prevent both lineages of nitrogen .
IDV infection, a consensus HEF DNA vaccine was 15 IDV Hemagglutination Inhibition ( HI ) Assay
designed . The HEF amino acid sequences of 19 IDVS
Guinea pig sera were treated with receptor -destroying
isolated between 2011 and 2016 were downloaded from
enzyme (RDE ; Denka Seiken , Tokyo, Japan ) before the HI
GenBank, from which the consensus sequence ( 664 amino assay
was performed. The RDE treatment was done accord
acids ) ( SEQ ID NO . 1 ) was calculated using BioEdit (Ver
sion 7.2.0) . Codons of the consensus HEF gene were opti- 20 ing to the manufacturer's protocol and the hemagglutination
mized for efficient expression in mammalian cells by using inhibition assay was performed using our previously
an online tool ( JCat found online at jcat.de ). After codon described method ( 11 ) . The HI assay was performed against
optimization, the consensus HEF gene ( SEQ ID NO . 2 ) was the two representative IDV lineage viruses (D /swine/Okla
synthesized (GENEWIZ LLC , NJ , USA) and inserted into homa/ 1334/ 2011 ; D /bovine/Oklahoma /660 /2013 ) using 1 %
the pJW4303 expression vector, which was kindly provided 25 turkey red blood cells (RBCs ) ( Lampire Biological Labo
by Dr. Shan Lu (University of Massachusetts Medical ratories, Pipersville, Pa . , USA) .
School, Massachusetts, USA) . The constructed plasmid with
Real - Time qRT -PCR
the HEF insert was designated as FluD - Vax and the same
plasmid without the HEF insert was used as vector control.
Primers and probe were designed to target a conserved
FluD - Vax and control plasmid DNA were prepared by using 30 region of the NP gene ( Table 2 ) . A recombinant plasmid ,
an EndoFree Plasmid Giga Kit (Cat # 12391 , Qiagen , Ger- containing the full- length NP sequence of the IDV strain
D/ swine/Oklahoma/ 1334 / 2011
(accession
number :
many) for guinea pig vaccination .
Experiment Design
JQ922306 ) , was serially diluted and used as qRT- PCR
Guinea pigs were randomly divided into four groups ( 6 standard . Snap - frozen lung tissue was put into 2 ml tube
per group ). Animals in vaccine groups ( Vac 1 and Vac 2 ) 35 pre - filled with stainless steel beads (RNA -WISTO1, WIS
were inoculated into tibialis anterior muscle with FluD - Vax BIOMED LLC , CA ) and homogenized for 2 min using a
( 200 ug / animal) 4 times at 4 -week intervals, and animals in MiniBeadBeater - 16 ( BioSpec Products , Inc. OK) . RNA
the control groups (Ctr 1 and Ctr 2 ) were inoculated with the from homogenized lung tissues and plasma specimens was
same quantity of control plasmid DNA in parallel. A detailed extracted using a QIAamp Viral RNA Mini Kit (Cat # 52906 ,
vaccination schedule is shown in Table 1 .
Qiagen, Germany). The qRT- PCR reaction was performed in
TABLE 1
Guinea pig vaccination schedule

Group

week 1

week 4

Vac 1 (n = 6) ConD HEF, ConD HEF,
200 ug each 200 ug each
mock ,
mock,
Ctr 1 ( n = 6 )
200 ug each 200 ug each
Vac 2 (n 6 ) ConD HEF, ConD HEF,
200 ug each 200 ug each
mock ,
mock ,
Ctr 2 ( n = 6)
=

week 8

week 12

week 16

ConD HEF, ConD HEF, Challenged with
200 ug each 200 ug each IDV - D /OK , 3E5
mock ,
mock,
TCID50 /300 ul
200 ug each 200 ug each
ConD HEF, ConD HEF ,

Challenged with

200 ug each 200 ug each IDV - D /660, 3E5
mock ,

200 ug each 200 ug each 200 ug each

mock ,

200 ug each

TCID50 /300 ul

55
IDV Challenge and Sample Collection
To test the protective efficacy of FluD - Vax against two
lineages of IDV, animals in the Vac 1 and Ctr 1 groups were
challenged with a IDV DIOK lineage -representative strain
( D /swine /Oklahoma/1334 /2011, D/ OK) and Vac 2 and Ctr 2
groups
were challenged with a D /660 lineage-representative 60
strain ( D /bovine / Oklahoma/660/ 2013, D/ 660 ) ( Table 1 ) .
IDV stocks were prepared as previously reported ( 11 ) and
diluted in PBS containing 100 units /ml penicillin , 100 ug /ml

20 ul containing 1x TaqMan® Fast Virus 1 -Step Master Mix

(Cat # 4444434 , Thermo Fisher Scientific, USA) , 500 nM of
each primer, 250 nM of probe , and 5 ul total RNA extracted

from supernatants of homogenized guinea pig lung tissues .

atdenaturation
50° C. forstep
5 minat , 95followed
by RT inactivation / initial
° C. for 20 s and 45 cycles of

denaturation at 95 ° C. for 3 s and annealing/ extension at 60 °
C. for 30 s . Fluorescence signal was detected after the
streptomycin , and 0.3 % BSA (PBS - PS - BA) . A 300 ul vol- annealing / extension step at each cycle . All PCR assays were
ume of IDV inoculum containing 3E5 TCIDso was instilled 65 performed on the CFX96 Real - Time PCR System ( Bio - Rad,
into the nostrils ( 150 ul on each side) at 30 days post final California , USA) . The lower limit of detection for this
immunization . After IDV challenge , the animal head and method was verified to be around 10 copies / reaction .
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TABLE 2
Primers and probe for Real - Time PCR

.ligo

Sequence

NP_Forward

5 ' - AAGCGACGTTCCAAGAACTG

3

NP_Reverse

5 ' -GGGACTGCAACAGAACCATC

4

1716-1697

NP_probe

5 ' Fam - TGCTCCGGCACCTTGCCTTCC - 3'Tamra

5

1647-1627

SEQ ID NO . Position
1542-1561

" Numbering is from the sequence of D / swine / .klahoma / 1334 / 2011 PB1 gene , accession
number : JQ922306 .

In Situ Hybridization ( ISH )

IDV in respiratory tract tissues was detected using in situ 15
hybridization ( ISH ) with radioactive isotopes of sulfur ( SS )
labeled negative-sense RNA probes of HEF and nucleoprotein (NP ). HEF ( 1071 bp ) and NP ( 1024 bp ) cDNA templates
were amplified from D/ OK HEF and NP gene plasmids
using PCR with the following primer pairs containing poly- 20
sequences :
HEF - forward
AACGTGTAATACGACTCACTATAGGG

merase

primer - T7:

antibody titers of two groups at multiple time points were

compared by two -way ANOVA . Data are presented as
statistically significant.
Results
Phylogenetic and Antigenic Analysis of Consensus IDV
HEF Protein

mean : SD in FIG . 2 and FIG . 3. P <0.05 was considered as

IDV is similar to ICV in that it uses only one hemagglu

tinin - esterase - fusion glycoprotein (HEF ) spike for receptor
AGGGGCTTCGTTGATGTTGT ( SEQ ID No. 6 ) and HEF binding, receptor destruction , and membrane fusion ( 14 ) .
reverse
primer -SP6 : AACTGGATTTAGGTGACAC- The surface HEF thus represents a key protective immuno
TATAG AAGATCCTTGTTGCTGGCGT ( SEQ ID NO . 7 ) , 25 gen for the development of a preventive vaccine . Two
NP - forward primer- T7 : AACGTGTAATACGACTCAC- lineages of IDVs are primarily responsible for current IDV
TATAGGG TGGCAAGCAAAAAGAACGGG ( SEQ ID global infections ( 1 , 3 , 13 ) . Furthermore, these two distinct
NO . 8 ) , and NP - reverse primer- 5P6 : AACTGGATT- lineages of IDVs can also co - infect the same animals (3 , 20) .
TAGGTGACACTATAGA

CCTCTTTTCTTGGGCTGGGA ( SEQ ID NO . 9 ) . Negative
sense riboprobes from HEF and NP were generated by in
vitro run -off transcription with SP6 RNA polymerase and
were used for detection of viral transcripts. Six -micron
tissue sections were cut and ISH was conducted by following our previously published method ( 18 ) . Slides were
exposed for 3 days in radioautography and counter -stained
with hematoxylin and eosin . Tissue sections were digitized
using Scanscope and IDV RNA positivity was reviewed by
two investigators independently. The specificity of IDV
riboprobes were confirmed using HIV - 1 riboprobes as a
negative control probe and rhesus lung tissues as negative
control tissues .
Combined Immunohistochemical Staining and ISH
To determine the cell type of IDV infected cells , a
combination of immunohistochemical staining ( IHCS ) and
ISH was performed as previously described ( 19 ) . A pancytokeratin rabbit polyclonal antibody (MA5-13203, 1 : 150 ,
Invitrogen ) and diaminobenzidine (DAB ) with the Dako
Envision and Peroxidase kit was used for IHCS . Stained
tissue sections were digitized using Scanscope and viral
RNA ISH signal and immunohistochemically stained epithelial cell signal was viewed in single color channel and
combined color channels using Aperio's Spectrum Plus
analysis program ( version 9.1 ; Aperio ePathology Solutions ) .

In Situ Cell Death Detection by TUNEL Assay
To detect apoptotic cell death in lung tissues , terminal
deoxynucleotidyl transferase dUTP nick end labeling

To develop an IDV vaccine that could prevent infection from
30 both lineages of IDV, we designed and constructed an IDV
HEF consensus gene ( ConD - HEF ) based vaccine , named as
FluD - Vax . Phylogenetic analysis showed that the amino acid
sequence of ConD - HEF resembles both lineages , but is
closer to the lineage represented by strain D /swine/Okla
35 homa/ 1334/ 2011 ( D/OK) than the lineage represented by
strain D /bovine /Oklahoma /660 /2013 ( D/ 660) ( FIG . 1 ) . As
shown in FIG . 1 , the phylogenetic relationship of HEF
amino acid sequences between consensus vaccine (ConD
HEF ) and 19 IDVs isolates was illustrated in a N - J phylog
40 eny plot ( left panel) and a Highlighter plot ( right panel ). In
the phylogeny plot , the consensus HEF was depicted as a
closed red circle , D / swine/ Oklahoma / 1334 / 2011 (D/ OK) as
an open blue circle and D /bovine /Oklahoma/660 / 2013
(D/ 660 ) as an open green circle . Bar length represented
45 0.005 amino acid substitutions per site . Amino acid poly
morphisms in the highlighter plot were indicated by a
colored mark . The phylogenetic distance ( average substitu
tions per amino acid) of ConD -HEF to D/ OK is 0.5 % and
D/ 660 is 2.6 % . The antigenicity of the consensus HEF
50 protein expressed by the FluD - Vax was assessed by West
ern -blotting. Our data showed that both the full -length HEF
and the cleaved HEF1 ( 16 ) could be recognized by rabbit
anti- IDV sera .
FluD - Vax elicited robust HI antibody responses against
55 both D/OK and D/ 660 lineages
As illustrated in Table 1 , the guinea pigs in the vaccine
and control groups were immunized with FluD - Vax or
control plasmid DNA , respectively, 4 times at 4 - week inter
vals . Peripheral blood was collected at 3 weeks post each
60 vaccination
for evaluation ofHEF -specific neutralizing anti
bodies against D/ OK and D/ 660 using hemagglutination
inhibition ( HI ) assay. The HI antibody titers against both
IDVs increased significantly after the second immunizations
and peaked after the third immunization . The mean titer of

( TUNEL ) assay was performed as we previously described
(910
19 )., In
situ cell death detection AP Kit (Cat # 11-684 809
Roche ) and AP substrate (RNAscope® 2.0 HD Detection Kit , RED , ACD ) were used to immunochemically detect
TUNEL -positive apoptotic cells as red color signals. The
stained tissue sections were digitized using Scanscope.
Statistical Analysis
65 HI antibodies against D/OK was higher than D/ 660 after
Statistical analyses were performed using GraphPad each vaccine immunization ( FIGS . 2A and 2B ) . Control
Prism 6.0 (GraphPad Software , California , USA) . The HI groups did not generate a detectable HI antibody response at

US 10,960,069 B2
25

26

any time point (Data not shown) . ConD - HEF vaccine RNA ), indicating IDV from the respiratory tract can spread
induced robust HI antibody responses against D/OK and into peripheral blood if the IDV virus burden is very high .
D /660 in both vaccine groups . However, the mean magni- However, none of any other animals in the vaccine and
tudes against D/ OK were higher than against D**/,660 over the control groups had detectable IDV RNA in plasma . To
course
of immunization ( * : P <0.1 ,
P <0.01 , 5 confirm qRT-PCR results, we detected viral RNA in respi
*** : P <0.001 ) . Interestingly , after the final vaccination , the ratory tract tissues collected from euthanized animals using
mean HI antibody titers to D/OK or D/ 660 between the two in situ hybridization ( ISH ) . Consistent with the qRT-PCR
vaccine groups ( Vac 1 and Vac 2 ) were similar (FIG . 2C ) , results, ISH confirmed that all of the animals in the control
indicating that our vaccine induced a similar - level of groups
infected after IDV intranasal challenge , evident
immune responses between the Vacl and Vac2 groups. In 10 by the were
presence
of abundant IDV VRNA positive cells in
addition , we also calculated the relative HI antibody titers of respiratory tract tissues
, such as in lung (FIG . 4 ) and nasal
D/ 660 to D/ OK and found the mean ratio of D/ 660 versus
turbinate
and
tracheal
tissues
(FIG . 5 ) . The presence of IDV
D/ OK HI titers was 0.67 ( FIG . 2D ) . The relative HI titers VRNA positive cells in nasal turbinate
, septum , trachea , and
were calculated by normalizing D/ 660 HI titer to D/OK HI

titer
for each individual animal. Error bars represent stan- 15 upper
lung tissues
, further confirmed that IDV can infect both the
and lower respiratory tract . Of note , IDV has a
dard deviations .
To generate the pictures in FIG . 2E , the hemagglutinin
esterase - fusion protein ( HEFP ) structure of influenza D
virus (PDB ID 5e64 ) was selected as a template , and all
models received QMEAN value -0.45 . The trimer formation 20

was made refereeing HEFP structure of influenza C virus
( 1fic ). One subunit was colored in white , while other two
were in light green . Graphics were prepared by the PyMOL
Molecular Graphics System , Version 1.8 Schrodinger, LLC
( New York , N.Y., USA) .
Efficacy of FluD - Vax Protection Against IDV Infections
To evaluate the protective efficacy of consensus FluD - Vax
vaccine against two lineages of IDV infection, the guinea
pigs in the Vac 1 and Ctr 1 groups were challenged with IDV
D/ OK and the Vac 2 and Ctr 2 groups were challenged with
IDV D/ 660 . A minimal loss of body weight (< 5 % on
average) post viral challenge occurred in all groups with a
slightly more reduction in body weight observed in the
vaccine group after D/OK challenge compared to the control
group . The body temperature of animals in both vaccine and
control groups remained stable without significant fluctua
tion FIG . 3 ) .
To measure IDV infection , qRT -PCR and ISH were used
to detect viral RNA in respiratory tract tissues collected from
euthanized animals . Most IDV quantitative real - time PCR
assays were designed based on the originally isolated PB1
sequence (4 ) . Recently, Faccini S and colleagues improved
this assay by targeting the primers and probe to the highly
conserved segment of PB1 ( 21 ) . Like PB1 , NP is another
conserved gene in influenza viruses including IDV, which
has been a primary target for RT - PCR assay development.
The new method developed in our study can serve as an
alternative to the RT -PCR assay targeting the PB1 gene as
published previously. In addition , there were other reasons
make us develop the current NP gene based real- time PCR
method . We did not have the PB1 standard used in the
aforementioned assay , therefore, we developed a NP gene
based real - time PCR method . High viral loads were readily
detected using qRT- PCR in all the lung tissues of guinea pigs
from both control groups, immunized with a sham vaccine
and challenged with either D/ OK or D/ 660 IDV. The mean
viral RNA load in the D/OK control group (Mean + SD ,
7.41 + 0.81 , log 10) was significantly higher than the D/ 660
control group ( 5.52 : 2.52 ) (FIG . 3 ) . In contrast, no IDV viral
RNA was detected in any lung tissues from the vaccine
groups , immunized with FluD - Vax and challenged with
either D/OK or D/ 660 IDV (FIG . 3 ) . To investigate whether
IDV exists in peripheral blood in IDV infected animals , we
conducted qRT-PCR and found that one animal was IDV
positive in plasma ( 4.49E10 copies/ml ) . The animal with
IDV positive plasma was infected with D/OK and had the
highest viral load in lung tissues ( 8.5E10 copies/ ug total

predisposition to infect the lungs ( FIGS . 4 & 5 ) . As shown

in the FIGS . 4 & 5 , both lineage representative IDVs
VRNA + cells found in bronchioles than alveoli . Represen

infected bronchioles and alveoli of lung tissues with more

tative images of FIG . 5 show that no IDV RNA + cells (black
silver grains in radioautographs, red arrows) were detected
in any nasal turbinate (E & F, animal 1099 ) and tracheal
tissues (G & H , animal 1099 ) of animals who received the
25 FluD - Vax vaccine and were subsequently challenged with
IDV D/ OK or D/ 660 . IDV RNA + cells (black silver grains
in radioautographs) were detected in nasal turbinate ( A & B ,
animal 1084 ) and tracheal tissues ( C & D , animal 1099 ) of
control animals who received the sham vaccine and were

30 subsequently challenged with IDV D/ OK or D/ 660 . Insets
are magnified in images marked by shown arrows . As

expected , we did not find IDV infected cells in the draining
lymph node tissues of the lungs. Pan -cytokeratin immuno
35 histochemical staining in combination with ISH confirmed

that IDV infected cells were epithelial cells (FIG . 6 ) . In FIG .
6 , representative images show epithelial cells in lung tissues
that were immunohistochemically stained as brown ( Brown ,
in B , C , E , & F, animal 1084 ) with a pan -cytokeratin
40 antibody and with IDV RNA underlaid of silver grains in
radioautographs as cyan , yellow , or black color ( red arrows)
with different channel separation.
IDV Infection Caused Apoptosis in Lung Tissues
To determine whether IDV infection could cause pro
45 gramed cell death in lung tissues , we conducted TUNEL

50

55

60

65

assays on lung tissues from all of the animals in the vaccine
and control groups. We detected apoptotic cells in lung
tissues on days 5 and 7 post IDV D/ 660 (FIG . 7C - F ) and
D/OK ( FIG . 71 - L ) infection in animals from the control
groups. TUNEL -positive cells were mainly localized in the
epithelial cells lining alveoli (FIGS . 7C , E , I & K , black
arrows) and bronchioles (FIGS . 7D , F, H & L , black arrows
within blue circles). However, TUNEL -positive cells were
also detected in non -epithelial cells ( FIG . 7 , green arrows).
In contrast, we did not observe TUNEL -positive cells in
animals from the vaccine group (FIGS . 7A - B & G - H ) .
Discussion
The newly identified influenza D virus (DV) has been
demonstrated to infect economically important domestic
livestock , such as swine and cattle. IDV infection has been
reported to be significantly associated with bovine respira
tory disease complex ( BRDC ) , which is the most economi
cally significant disease affecting the U.S. cattle industry .
While the level of infectivity and pathogenicity of IDV to
humans remains to be determined , IDV has the potential to
infect humans . IDV seroprevalence was estimated to be over

90% in individuals working closely with cattle. Moreover,
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IDV has a broad host range , which could enable IDV to gain D /OK and D/ 660 intranasal challenge, indicating vaccine
virulence due to continual mutation , recombination , and elicited immunity is potent enough to protect against both
evolution .
lineages of IDV infection (FIG . 3-5 ) . In the FIG . 4 figures,
The development of a protective IDV vaccine is needed . IDV RNA + cells ( black silver grains in radioautographs)
However, the development of an effective vaccine is not 5 were detected in all of the lung tissues of animals who
simple, as a previous study showed that a chemical inacti- received the sham vaccine ( control) and subsequently chal
vated IDV vaccine did not provide sterilizing protection lenged intranasally with IDV DIOK ( A - C , animal 1084 ) or
against even homologous virus challenge in bovine . As D/ 660 ( G - I , animal 1091 ) , but were not detected in any lung
aforementioned , two genetically and serologically distinct tissues of animals who received the FluD - Vax vaccine and
lineages of IDV have been found to be co - circulating in 10 subsequently challenged with IDV D/ OK (D - F, animal
cattle and equine. Therefore , This disclosure describes the 1099 ) or D/ 660 (J - L , animal 1106 ) . Red insets in the middle
development of a vaccine that could prevent infection by panel are magnified and shown in the left and right panels.
both lineages of IDV. Consensus sequence -based vaccine is In contrast, all animals in the control groups were infected
a widely used approach to minimize the sequence diversity after IDV challenge.
between a vaccine strain and circulating viruses, which can 15 After D/ OK and D/ 660 challenge , infected animals in the
create an artificial sequence to " centralize ” the immunoge- control groups had higher viral RNA loads in respiratory
nicity of the vaccine antigen. In addition to the consensus tissues at 5 dpi than 7 dpi by both q -RT- PCR and ISH assays,
sequence - based vaccine development approach, " ancestor which is consistent with our previous study. IDV RNA cells
and ' center of the tree ' methods have also been applied to were detected in nasal turbinate , nasal septum , trachea , and

minimize the distance /mismatch of antigens between a vac- 20 lung tissues , indicating IDV can infect and replicate within
cine and circulating viruses . As previously reported, when

designing a consensus vaccine from the sequences of a
symmetric phylogeny, these three methods generate very

similar sequences . However, if the original sequences are

the entire respiratory tract. Notably, within lung tissues , viral
RNA + cells were detected in both alveoli and bronchioles,
but more in bronchiolar cells . Using a combination of IHCS
and ISH , it was shown that IDV solely infected epithelial

from an asymmetric phylogeny, the consensus sequence will 25 cells . Although the exact protective mechanisms of the

have a bias toward the dominant cluster of the input. In this consensus vaccine against prevalent lineages of IDV infec
study, a DNA vaccine encoding consensus IDV HEF protein tion was not fully investigated in this study, the results
( ConD - HEF ) was designed and constructed . HEF surface revealed that protection is correlated with HI antibody
protein was chosen for its key role in receptor binding, responses. One concern during IDV vaccine design is the
receptor destruction , and membrane fusion . Phylogenetic 30 potential for escape mutations that could minimize protec
analysis showed that ConD - HEF is close to the center of the tion . However, the DNA vaccine expressing consensus IDV
IDV phylogenetic tree with a slight bias toward the lineage HEF in this study provided complete protection and pre
represented by D/OK ( FIG . 1 ) . No further optimization was vented the occurrence of IDV escape mutations. However,
done to reduce this bias , because in natural infection, D/OK IDV mutations can readily develop during IDV natural
could generate relatively higher cross - reactive antibodies to 35 infection , thus a broad understanding of potentially mutated
D /660 represented lineage than D /660 to D /OK . In this antigenic sites in IDV vaccine design is important.
study, 19 full - length IDV HEFs were used for the consensus
The data suggested that the consensus HEF may be a good
vaccine design, including the 10 sequences that were pre- immunogen to protect against different lineages of IDV in
viously analyzed for the identification of the two major large animals or even in humans. Further investigation is
circulating lineages (D/OK and D/ 660 ) . For future vaccine 40 warranted to compare its efficacy with other vaccine modali
design , including additional viral sequences, especially ties , such as inactivated and vectored vaccines.

sequences that were isolated from different geographic locaCurrently, the pathogenesis and resulting consequences of
tions , may further optimize the coverage of a consensus IDV infection in economically important animals are largely
DNA IDV vaccine .
unknown. Apoptosis has been demonstrated to be an impor
A previous study by this team established a guinea 45 tant anti - viral host defense to restrict influenza A and B virus
pigs/ IDV model . With this model humoral immune replication . Paradoxically, apoptosis has also been impli

responses elicited by the consensus HEF DNA vaccine

cated in inducing respiratory tissue damage during influenza

(FluD - Vax ) were evaluated . HI antibodies in blood against
both D/ OK and D/ 660 IDVs were detectable after the first

virus infection . It was found for the first time that IDV
infection induced TUNEL -positive apoptotic cells in epithe

immunization , were significantly boosted after the second 50 lial cells lining alveoli ( FIGS . 7C , E , I & K , black arrows)
immunization ( > 1:40 ) , and peaked after the third immuni- and bronchioles ( FIGS . 7D , F , H & L , black arrows within
zation (FIGS . 2A and 2B ) . In this proof-of-concept study, in blue dotted circles ) in lung tissues of infected animals .
order to induce optimal humoral responses and achieve Furthermore, we observed TUNEL -positive non -epithelial
better protection, immunization was done 4 times . However, cells ( FIG . 7 , green arrows ). Our results demonstrate that

sterilizing protection may be induced by less than 4 immu- 55 IDV infection causes apoptosis in lung tissues . Nevertheless,
the dichotomy of protective and detrimental roles of apop
minimal number of immunizations to achieve sterilizing tosis during IDV infection remains to be defined in future

nizations and future studies are needed to determine the

protection. A more robust HI antibody responses against studies .
In summary , this study has demonstrated that a DNA
D/ OK than against D/ 660 ( FIG . 2 ) was observed, which may
be due to the intentional phylogenetic bias design of our 60 vaccine expressing consensus IDV HEF can provide com
consensus vaccine to D/OK . In silico comparative modeling plete protection, which is correlated with HEF -specific anti
of D/ OK , D/ 660 and ConD HEF protein structures by body responses in a guinea pig model . Further, this study
SWISS - MODEL server as performed and found several clearly demonstrated that IDV infects epithelial cells of both
amino acid substitutions in the receptor binding site of the upper and lower respiratory tract, including alveoli and
D/ 660 HEF ( FIG . 2E ) . Although the consensus DNA vac- 65 bronchioles in lung tissues . More importantly, we found for
cine elicited various levels of HI antibodies against D/OK the first time that IDV infection can induce programed cell
and D/ 660 , it protected all vaccinated animals from IDV death in lung tissues .
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SEQUENCE LISTING
< 160 > NUMBER OF SEQ ID NOS : 9

< 210 > SEQ ID NO 1
< 211 > LENGTH : 664
< 212 > TYPE : PRT

< 213 > ORGANISM : Artificial Sequence
< 220 > FEATURE :

< 223 > OTHER INFORMATION : consensus sequence of hemagglutinin esterase
fusion protein of IDV

< 400 > SEQUENCE : 1

Met Phe Leu Leu Leu Ala Thr Ile Thr Ala Ile Thr Ala Cys Gin Ala
10

5

1

15

Glu Arg Glu Leu Ile Cys Ile Val Gln Arg Val Asn Glu Ser Phe Ser
25

20

30

Leu His Ser Gly Phe Gly Gly Asn Val Tyr Ser Met Lys Thr Glu Pro
35

40

45

Met Thr Gly Phe Thr Asn Val Thr Lys Gly Ala Ser Val Ile Asn Gln
55

50

60

Lys Asp Trp Ile Gly Phe Gly Asp Ser Arg Thr Asp Leu Thr Asn Asp
65

70

75

80

Gin Phe Pro Ala Ser Ser Asp Val Pro Leu Ala Val Ala Lys Lys Phe
90

85

95

Arg Ser Leu Ser Gly Ala Ser Leu Met Leu Ser Ala Phe Gly Pro Pro
100

105

110

Gly Lys Val Asp Tyr Leu Tyr Gin Gly Cys Gly Lys Glu Lys Val Phe
120

115

125

Tyr Glu Gly Val Asn Trp Ser Pro Glu Ala Gly Ile Asp Cys Phe Gly
140

135

130

Ser Asn Trp Thr Gin Thr Lys Lys Asp Phe Tyr Ser Arg Ile Tyr Glu
145

155

150

160

Ala Ala Arg Gly Ser Thr Cys Met Thr Leu Val Asn Ser Leu Asp Thr
165

175

170

Lys Ile Ser Ser Thr Thr Ala Thr Ala Gly Thr Ala Ser Ser Cys Ser
185

180

190

Ser Ser Trp Met Lys Ser Pro Leu Trp Tyr Ala Glu Ser Ser Val Asn
195

200

205

Pro Gly Ala Lys Pro Gin Val Cys Gly Thr Glu Gin Ser Ala Thr Phe
210

220

215

Thr Leu Pro Thr Ser Phe Gly Ile Tyr Lys Cys Asn Lys His Val Val
225

235

230

240

Gin Leu Cys Tyr Phe Val Tyr Glu Asn Lys Thr Thr Phe Asn Thr Phe
245

255

250

Gly Cys Gly Asp Tyr Tyr Gln Asn Tyr Tyr Asp Gly Asn Gly Asn Leu
260

270

265

Ile Gly Gly Met Asp Asn Arg Val Ala Ala Tyr Arg Gly Ile Ala Asn
275

285

280

Ala Gly Val Lys Ile Glu Cys Pro Ser Lys Ile Leu Asn Pro Gly Thr
300

295

290

Tyr Ser Ile Arg Ser Thr Pro Arg Phe Leu Leu Val Pro Lys Arg Ser
305

315

310

320

Tyr Cys Phe Asp Thr Asp Gly Gly Tyr Pro Ile Gin Val Val Gin Ser
325

330

335

Glu Trp Ser Ala Ser Arg Arg Ser Asp Asn Ala Thr Glu Glu Ala Cys
340

345

350
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- continued
Leu Gin Thr Glu Gly Cys Ile Phe Ile Lys Lys Thr Thr Pro Tyr Val
365

360

355

Gly Glu Ala Asp Asp Asn His Gly Asp Ile Glu Met Arg Gin Leu Leu
370

380

375

Ser Gly Leu Gly Asn Asn Asp Thr Val Cys Val Ser Gin Ser Gly Tyr
385

390

395

400

Thr Lys Gly Glu Thr Pro Phe Val Lys Asp Tyr Leu Ser Pro Pro Lys
405

410

415

Tyr Gly Arg Cys Gin Leu Lys Thr Asp Ser Gly Arg Ile Pro Thr Leu
425

420

430

Pro Ser Gly Leu Ile Ile Pro Gin Ala Gly Thr Asp Ser Leu Met Arg
435

440

445

Thr Leu Thr Pro Ala Thr Arg Ile Phe Gly Ile Asp Asp Leu Ile Phe
455

450

460

Gly Leu Leu Phe Val Gly Phe Val Ala Gly Gly Val Ala Gly Gly Tyr
465

470

475

480

Phe Trp Gly Arg Ser Asn Gly Gly Gly Gly Gly Ala Ser Val Ser Ser
485

495

490

Thr Gin Ala Gly Phe Asp Lys Ile Gly Lys Asp Ile Gin Gin Leu Arg
500

505

510

Asn Asp Thr Asn Ala Ala Ile Glu Gly Phe Asn Gly Arg Ile Ala His
520

515

525

Asp Glu Gin Ala Ile Lys Asn Leu Ala Lys Glu Ile Glu Asp Ala Arg
535

530

540

Ala Glu Ala Leu Val Gly Glu Leu Gly Ile Ile Arg Ser Leu Ile Val
545

550

560

555

Ala Asn Ile Ser Met Asn Leu Lys Glu Ser Leu Tyr Glu Leu Ala Asn
565

575

570

Gin Ile Thr Lys Arg Gly Gly Gly Ile Ala Gln Glu Ala Gly Pro Gly
585

580

590

Cys Trp Tyr Val Asp Ser Glu Asn Cys Asp Ala Ser Cys Lys Glu Tyr
600

595

605

Ile Phe Asn Phe Asn Gly Ser Ala Thr Val Pro Thr Leu Arg Pro Val
615

610

620

Asp Thr Lys Val Val Ile Thr Ser Asp Pro Tyr Tyr Leu ly Ser Thr
630

625

640

635

Ile Ala Leu Cys Leu Leu Gly Leu Val Ala Ile Ala Ala Ser Val Gly
645

650

655

Val Ile Trp Ile Cys Cys Lys Lys
660

< 210 > SEQ ID NO 2
< 211 > LENGTH : 1995
< 212 > TYPE : DNA

< 213 > ORGANISM : Artificial Sequence
< 220 > FEATURE :

< 223 > OTHER INFORMATION : Consensus nucleotide sequence of hemagglutinin
esterase fusion protein of IDV

< 400 > SEQUENCE : 2

atgttcctgc tgctggccac catcaccgcc atcaccgcct gccaggccga gagggagctg

60

atctgcatcg tgcagagggt gaacgagagc ttcagcctgc acagcggctt cggcggcaac

120

gtgtacagca tgaagaccga gcccatgacc ggcttcacca acgtgaccaa gggcgccagc

180

gtgatcaacc agaaggactg gatcggettc ggcgacagca ggaccgacct gaccaacgac

240
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cagttccccg ccagcagoga cgtgcccctg gccgtggcca agaagttcag gagcctgage

300

ggcgccagcc tgatgctgag cgccttcggc ccccccggca aggtggacta cctgtaccag

360

ggctgcggca aggagaaggt gttctacgag ggcgtgaact ggagccccga ggccggcatc

420

gactgcttcg gcagcaactg gacccagacc aagaaggact tctacagcag gatctacgag

480

gccgccaggg gcagcacctg catgaccctg gtgaacagcc tggacaccaa gatcagcago

540

accaccgcca ccgccggcac cgccagcagc tgcagcagca gctggatgaa gagccccctg

600

tggtacgccg agagcagcgt gaaccccggc gocaagcccc aggtgtgcgg caccgagcag

660

agcgccacct tcaccctgcc caccagcttc ggcatctaca agtgcaacaa gcacgtggtg

720

cagctgtgct acttcgtgta cgagaacaag accaccttca acaccttcgg ctgcggcgac
tactaccaga actactacga cggcaacggc aacctgatog goggcatgga caacagggtg

780
840

gccgcctaca ggggcatcgc caacgccggc gtgaagatcg agtgccccag caagatcctg

900

aaccccggca cctacagcat caggagcacc cccaggttcc tgctggtgcc caagaggagc

960

tactgcttcg acaccgacgg cggctacccc atccaggtgg tgcagagcga gtggagcgcc

1020

agcaggagga gcgacaacgc caccgaggag gcctgcctgc agaccgaggg ctgcatcttc

1080

atcaagaaga ccacccccta cgtgggcgag gccgacgaca accacggcga catcgagatg

1140

aggcagctgc tgagcggcct gggcaacaac gacaccgtgt gcgtgagcca gagoggctac

1200

accaagggcg agaccccctt cgtgaaggac tacctgagcc cccccaagta cggcaggtgc

1260

cagctgaaga ccgacagcgg caggataccc accctgccca gcggcctgat catcccccag
gccggcaccg acagcctgat gaggaccctg acccccgcca ccaggatott cggcatcgac

1320

1380

gacctgatct tcggcctgct gttcgtgggc ttcgtggccg goggcgtggc cggcggctac

1440

ttctggggca ggagcaacgg cggcggcggc ggcgccagcg tgagcagcac ccaggccggc

1500

ttcgacaaga tcggcaagga catccagcag ctgaggaacg acaccaacgc cgccatcgag

1560

ggcttcaacg gcaggatcgc ccacgacgag caggccatca agaacctggc caaggagato

1620

gaggacgcca gggccgaggc cctggtgggc gagctgggca tcatcaggag cctgatcgtg

1680

gccaacatca gcatgaacct gaaggagagc ctgtacgagc tggccaacca gatcaccaag

1740

aggggcggcg gcatcgccca ggaggccggc cccggctgct ggtacgtgga cagcgagaac

1800

tgcgacgcca gctgcaagga gtacatcttc aacttcaacg gcagcgccac cgtgcccacc
ctgaggcccg tggacaccaa ggtggtgatc accagcgacc cctactacct gggcagcacc

1860

atcgccctgt gcctgctggg cctggtggcc atcgccgcca gcgtgggcgt gatctggato

1980

tgctgcaaga agtag

1995

1920

< 210 > SEQ ID NO 3
< 211 > LENGTH : 20
< 212 > TYPE : DNA

< 213 > ORGANISM : Artificial Sequence
< 220 > FEATURE :

< 223 > OTHER INFORMATION : artificial primer for IDV
< 400 > SEQUENCE :

3

aagcgacgtt ccaagaactg
< 210 > SEQ ID NO 4
< 211 > LENGTH : 20

< 212 > TYPE : DNA

< 213 > ORGANISM : Artificial Sequence
< 220 > FEATURE :

< 223 > OTHER INFORMATION : artificial primer for IDV

20

US 10,960,069 B2
36

35
- continued
< 400 > SEQUENCE : 4

gggactgcaa cagaaccato

20

< 210 > SEQ ID NO 5
< 211 > LENGTH : 21
< 212 > TYPE : DNA

< 213 > ORGANISM : Artificial Sequence
< 220 > FEATURE :

< 223 > OTHER INFORMATION : artificial primer for IDV
< 400 > SEQUENCE : 5

tgctccggca ccttgccttc c

21

< 210 > SEQ ID NO 6
< 211 > LENGTH : 46
< 212 > TYPE : DNA

< 213 > ORGANISM : Artificial Sequence
< 220 > FEATURE :

< 223 > OTHER INFORMATION : artificial primer for IDV
< 400 > SEQUENCE : 6

aacgtgtaat acgactcact atagggaggg gcttcgttga tgttgt

46

< 210 > SEQ ID NO 7
< 211 > LENGTH : 44
< 212 > TYPE : DNA

< 213 > ORGANISM : Artificial Sequence
< 220 > FEATURE :

< 223 > OTHER INFORMATION : artificial primer for IDV
< 400 > SEQUENCE : 7

aactggattt aggtgacact atagaagatc cttgttgctg gcgt

44

< 210 > SEQ ID NO 8
< 211 > LENGTH : 46
< 212 > TYPE : DNA

< 213 > ORGANISM : Artificial Sequence
< 220 > FEATURE :

< 223 > OTHER INFORMATION : artificial primer for IDV

< 400 > SEQUENCE : 8

aacgtgtaat acgactcact atagggtggc aagcaaaaag aacggg

46

< 210 > SEQ ID NO 9
< 211 > LENGTH : 45
< 212 > TYPE : DNA

< 213 > ORGANISM : Artificial Sequence
< 220 > FEATURE :

< 223 > OTHER INFORMATION : artificial primer for IDV
< 400 > SEQUENCE : 9

aactggattt aggtgacact atagacctct tttcttgggc tggga
What is claimed is :

45

4. The immunogenic composition of claim 1 , further

1. An immunogenic composition comprising a vector comprising a veterinary acceptable carrier.
having an insert comprising a hemagglutinin esterase - fusion
5. An immunogenic composition comprising a recombi
protein from the D/OK and D/ 660 strains of influenza D 60 nant hemagglutinin esterase - fusion (HEF ) protein from the
D/OK and D/ 660 strains of IDV.
virus ( IDV ).
2. The immunogenic composition of claim 1 , wherein said
6. The immunogenic composition of claim 5 , wherein said
insert has a nucleotide sequence having at least 85 % protein is expressed by a nucleotide sequence having at least
85 % sequence homology with SEQ ID NO . 2 .
sequence homology with SEQ ID NO . 2 .
3. The immunogenic composition of claim 1 , further 65 7. The immunogenic composition of claim 5 , wherein said
comprising at least one antigen from a pathogen other than protein has at least 85 % sequence homology with SEQ ID .
IDV.

NO . 1 .
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8. The immunogenic composition of claim 5 , further
comprising at least one antigen from a pathogen other than
IDV .
9. The immunogenic composition of claim 5 , further
comprising a veterinary acceptable carrier.
10. An immunogenic composition comprising a vector
having an insert comprising a hemagglutinin esterase - fusion
protein from influenza D virus ( IDV) , wherein said insert
has a nucleotide sequence having at least 85 % sequence
homology with SEQ ID NO . 2 .
11. The immunogenic composition of claim 10 , further
comprising
at least one antigen from a pathogen other than
IDV .
12. An immunogenic composition comprising a recombinant hemagglutinin esterase - fusion ( FIEF ) protein from
influenza D virus (IDV) wherein said protein is expressed by
a nucleotide sequence having at least 85 % sequence homol
ogy with SEQ ID NO . 2 .
13. The immunogenic composition of claim 12 , further
comprising at least one antigen from a pathogen other than
IDV .
14. A method of reducing the incidence or severity of IDV
infection in an animal comprising the steps of:
administering an effective amount of an immunogenic
composition to an animal in need thereof, wherein said

immunogenic composition is selected from the group
consisting of the immunogenic composition of claim 1 ,
the immunogenic composition of claim 5 , the immu
nogenic composition of claim 10 , the immunogenic
composition of claim 12 , and any combination thereof.
15. The method of claim 14 , wherein said administration
is delivered via injection , intranasally , or orally.
16. The method of claim 14 , wherein said administration
is performed more than one time .
17. The method of claim 14 , further comprising the step
of administering an antigen from another pathogen other
than IDV.
18. The method of claim 17 , wherein said antigen from

5

10

15

another pathogen other than IDV is combined with said
immunogenic composition .
19. The method of claim 14 , wherein said animal in need

thereof is selected from the group consisting of cows and
pigs .

20

20. The method of claim 14 , wherein said reducing the
incidence or severity of clinical signs of IDV infection is in
comparison to an animal that has not received an adminis
tration of said immunogenic composition .

